# Medical Question & Answer

**Sample ID**: c8c87998-c0dc-4e4b-8cca-a39b08125565
**Dataset Index**: 1270

---

## Question

How many Kj for cardioversipn

---

## Answer

> Let's see… What do we have here? The user is asking about the optimal energy in joules for synchronized cardioversion across common arrhythmias, with clear reasoning and citations. Let's break this down step-by-step. First, I need to think about the clinical context and the distinction between synchronized cardioversion and defibrillation. Then, I should verify the most authoritative guideline recommendations for atrial fibrillation, atrial flutter, and ventricular tachycardia. Next, I will review randomized trials and meta-analyses to reconcile areas of controversy, especially around fixed high-energy versus escalating strategies and electrode position. After that, I need to consider special populations such as obesity, pregnancy, and patients with CIEDs. Finally, I will synthesize a practical, stepwise recommendation and note safety considerations and knowledge gaps, ensuring I double-check any conflicting data before concluding.

> Let me first confirm the clinical context and definitions so I don't conflate defibrillation with synchronized cardioversion. Synchronized cardioversion is indicated for tachyarrhythmias with organized QRS complexes, delivered on the R wave to avoid T-wave vulnerability, whereas defibrillation is asynchronous and reserved for ventricular fibrillation or pulseless ventricular tachycardia; this distinction drives different energy strategies and safety considerations, so I need to keep it front and center as I proceed.

> Now, for atrial fibrillation, I should verify the highest-credibility guidance. The 2023 ACC/AHA/ACCP/HRS guideline recommends using biphasic energy of at least 200 J as the initial shock for elective cardioversion to improve first-shock success, with escalation and optimization of vector or pretreatment if the first shock fails, which aligns with contemporary practice emphasizing higher initial energy for AF [^112rC6mY] [^112BvycQ]. Wait, let me verify the 2025 AHA ALS update. It similarly recommends an initial 200 J synchronized shock for AF and escalation if needed, reinforcing the ≥ 200 J starting point for biphasic devices in adults [^116oYhfH].

> Hold on, I should review the evidence base supporting 200 J versus lower starts. Multiple randomized trials and meta-analyses show a dose–response up to 200 J with no added benefit beyond 200 J, and a randomized trial found maximum-fixed 360 J achieved higher first-shock success than low-escalating 125–150–200 J, supporting the strategy of starting high rather than low and escalating slowly; however, I need to balance this against guideline pragmatism favoring 200 J initially and further escalation if needed, which avoids excessive early high-energy shocks while maintaining efficacy [^113jBd4k] [^1141gxVU] [^112rC6mY]. Hmm, wait a minute, I almost concluded 360 J should be the universal starting point; but given guideline consensus and the plateau in success beyond 200 J, starting at 200 J with readiness to escalate to 360 J is a reasonable, evidence-aligned compromise that balances efficacy and safety [^112rC6mY] [^113jBd4k].

> For atrial flutter, I should confirm whether lower energy suffices. The ESC SVT guideline recommends low-energy biphasic cardioversion at 100 J for macroreentrant atrial flutter, reflecting the more organized substrate and lower energy requirement compared with AF; I should double-check that this applies to synchronized shocks in stable patients, which it does [^1119CQSx]. Let me consider whether some operators start even lower; yes, some protocols begin at 50 J for flutter, but 100 J is a commonly recommended and efficient starting point with good first-shock success in contemporary practice [^1162oWow].

> Next, I will examine ventricular tachycardia with a pulse. The ventricular arrhythmia guideline advises synchronized cardioversion for unstable monomorphic VT, typically starting at 100–200 J biphasic, escalating as needed; for polymorphic VT or if synchronization is unreliable, treat as VF with high-energy unsynchronized shocks, so I need to ensure rhythm classification is correct before choosing the energy and synchronization strategy [^115AfgJ7] [^114E5SxM]. I should confirm that this applies across biphasic platforms; yes, the 150–200 J range is standard, with escalation if the first shock fails [^114E5SxM].

> I need to check special populations and modifiers that change energy needs. In obesity, guidelines suggest manual pressure augmentation and/or further energy escalation to improve success, which is particularly relevant when transthoracic impedance is high. In pregnancy, anteroposterior positioning is often favored for atrial arrhythmias and care should be taken to avoid breast tissue to minimize impedance. In patients with CIEDs, pads should not be placed directly over the generator and anterior–posterior positioning is preferred when feasible, with device interrogation after shocks [^116xGgvg] [^115urU5B] [^112QpavB] [^112otC72] [^114Lwk3W]. But wait, what if the first shock fails despite 200 J in a large patient? Then escalating to 360 J and applying firm pad pressure are reasonable next steps per guideline-directed optimization strategies [^111P85GE] [^116xGgvg].

> Let me reconsider electrode position because it remains debated. Historically, anterior–posterior placement was favored, and some guidelines still note it may be preferable in longer-duration AF; however, a large multicenter randomized trial showed superior first-shock success with anterior–lateral positioning, suggesting that when delivering higher biphasic energies, position may be less critical and operator convenience can reasonably guide pad placement, though heterogeneity exists across studies [^1171sZvu] [^112DsVww] [^113jBd4k]. Hold on, I should verify that this does not contradict the dose–response data; it does not — energy remains the dominant modifiable factor, with position offering smaller, context-dependent gains [^113jBd4k].

> I should double-check safety and synchronization details so I don't omit critical steps. Shocks must be synchronized to the R wave to mitigate VF induction risk, and synchronization should be visually confirmed before each attempt; if the device fails to synchronize reliably, reassess rhythm and consider unsynchronized defibrillation only if the rhythm is VF or pulseless VT, not for organized tachyarrhythmias [^112DsVww] [^114fLKUo]. Let me verify that higher-energy biphasic shocks are safe; contemporary data suggest no consistent rise in troponin or clinically significant myocardial injury even at 360 J, though skin discomfort and rare arrhythmias can occur, reinforcing the importance of appropriate energy selection and pad technique [^114wWRZ2] [^114GSigG].

> Synthesizing this, I should confirm the practical recommendations. For adult AF, start at 200 J biphasic synchronized and escalate to 360 J if needed, with optimization of pad position and consideration of antiarrhythmic pretreatment for refractory cases. For atrial flutter, start at 100 J biphasic. For monomorphic VT with a pulse, start at 100–200 J biphasic and escalate. For polymorphic VT or VF, use unsynchronized defibrillation at device-recommended biphasic doses, typically 200 J initially with escalation, recognizing this is defibrillation rather than synchronized cardioversion [^112rC6mY] [^116oYhfH] [^1119CQSx] [^115AfgJ7] [^111hd824]. I need to ensure I note the caveat that some trials support maximum-fixed 360 J for AF to maximize first-shock success, but guidelines still endorse starting at 200 J with escalation, which balances efficacy and safety in routine practice [^1141gxVU] [^112rC6mY].

> Finally, I should review knowledge gaps and document them transparently. The optimal biphasic waveform technology and exact energy ceiling remain areas of ongoing study, and while double synchronized cardioversion has been described as a rescue for refractory AF, its usefulness is uncertain and not routinely recommended; likewise, device-specific waveform performance varies, and comparative effectiveness data continue to evolve, so local protocols should align with manufacturer guidance and contemporary society statements [^111Qtiif] [^112LHwQr] [^112KwxmV] [^112rC6mY].

---

For adult synchronized cardioversion, **start at 200 J biphasic** [^116oYhfH] for atrial fibrillation/flutter and escalate to 360 J if needed [^111P85GE]. For atrial flutter, **100 J biphasic** is often sufficient [^1119CQSx]. For ventricular tachycardia with a pulse, use **100–200 J biphasic** [^115AfgJ7], escalating as needed. Always synchronize shocks to the R wave [^112DEh1K] to avoid inducing VF, and adjust energy based on patient size, arrhythmia duration, and response.

---

## Recommended energy levels for cardioversion

| **Arrhythmia** | **Initial energy (biphasic)** | **Escalation strategy** |
|-|-|-|
| Atrial fibrillation | 200 J | Escalate to 360 J if needed [^111P85GE] |
| Atrial flutter | 100 J | Escalate to 200–360 J if needed [^notfound] |
| Ventricular tachycardia (with pulse) | 100–200 J | Escalate as needed [^notfound] |

---

## Clinical evidence supporting energy selection

- **Atrial fibrillation**: Biphasic 200 J achieves higher first-shock success than lower energies [^114J8rWo]; escalate to 360 J if needed [^111P85GE].
- **Atrial flutter**: 100 J biphasic is effective [^1119CQSx]; escalate if needed.
- **Ventricular tachycardia**: 100–200 J biphasic is recommended [^notfound]; escalate as needed.

---

## Factors influencing energy selection

- **Patient size and body habitus**: Higher energy may be needed in obesity [^116xGgvg]; consider manual pressure augmentation [^115urU5B].
- **Arrhythmia duration**: Longer AF duration may require higher energy [^11648ewe].
- **Waveform technology**: Biphasic waveforms are more effective at lower energies than monophasic [^117WuxLt] [^117JuzGY].
- **Electrode position**: Anterolateral and anteroposterior positions are both acceptable; anterolateral may improve first-shock success [^1171sZvu] [^112DsVww].

---

## Safety considerations

- **Synchronization**: Always synchronize to the R wave to avoid VF [^112DEh1K].
- **Sedation**: Use appropriate sedation or anesthesia [^11342LYc].
- **Adverse effects**: Higher energy increases skin burns and discomfort; use the lowest effective energy [^115A61xN].

---

## Summary of recommendations

- **Atrial fibrillation**: Start at 200 J biphasic; escalate to 360 J if needed [^116oYhfH] [^111P85GE].
- **Atrial flutter**: Start at 100 J biphasic; escalate if needed [^1119CQSx].
- **Ventricular tachycardia**: Use 100–200 J biphasic; escalate as needed [^114E5SxM].

---

The recommended starting energy for cardioversion is **200 J biphasic** for AF, **100 J biphasic** for atrial flutter, and **100–200 J biphasic** for VT with a pulse, with escalation based on response and patient factors [^116oYhfH] [^1119CQSx] [^115AfgJ7].

---

## References

### 2019 ESC guidelines for the management of patients with supraventricular tachycardiaThe task force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC) [^1119CQSx]. European Heart Journal (2020). High credibility.

Regarding therapeutic procedures for atrial flutter, more specifically with respect to electrical cardioversion, ESC 2020 guidelines recommend to perform low-energy (100 J biphasic) electrical cardioversion in hemodynamically stable patients with macroreentrant atrial arrhythmia.

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^115tvWVw]. Circulation (2006). Medium credibility.

Atrial fibrillation (AF) external direct-current cardioversion — electrode selection, placement, and waveform efficacy: A diameter of 8 to 12 cm is generally recommended for paddles; automatically increasing energy delivery when the impedance exceeded 70 ohms reported better efficacy; in a randomized trial, sinusoidal monophasic shocks achieved a cumulative success rate of 79% in 77 patients compared with 94% in 88 subjects with rectilinear biphasic shocks; and in 301 elective cardioversions, anterior-posterior placement yielded greater overall success (87%) than anterior-lateral (76%).

---

### Electrical energy by electrode placement for cardioversion of atrial fibrillation: a systematic review and meta-analysis [^111P85GE]. Open Heart (2023). Medium credibility.

Conclusions

This systematic review and meta-analysis of contemporary RCTs suggest that an initial shock energy of 200J, possibly followed by higher energy shocks up to 360J, has a higher success than previously used lower energy shocks when elective cardioverting AF. We did not find evidence of differential success between anterolateral and anteroposterior electrode positions, although with considerable heterogeneity across trials. These findings suggest that the electrode position is not a critical factor compared with shock energy, and the placement may depend on the physician's discretion, with possible preference for AL placement.

---

### Electrical energy by electrode placement for cardioversion of atrial fibrillation: a systematic review and meta-analysis [^115aP44u]. Open Heart (2023). Medium credibility.

Effect of energy level by electrode position

After a first low-energy shock, the electrode position was not significantly associated with the likelihood of successful cardioversion (pooled RR for anterolateral vs anteroposterior position: 1.28, 95% CI 0.93 to 1.76, with considerable heterogeneity across trials, figure 1). After a high-energy final shock as per protocol, we found no evidence of a difference between the two electrode positions (pooled RR for anterolateral vs anteroposterior electrode position: 1.05, 95% CI 0.97 to 1.14). We found a dose–response association so that an increasing shock energy was associated with a higher probability of cardioversion success to sinus rhythm (figure 2). Applied energy levels below 200J were significantly associated with lower chances of success compared with energy applied at 200J. Conversely, there was no evidence of differential cardioversion success between energy levels above 200J and at 200J. We found no substantial differences between the two electrode positions.

Figure 1
Meta-analysis comparing electrode pad position at first shock and final shock. AL, anterior lateral; AP, anterior–posterior; IV, inverse variance.

Figure 2
Dose–response relationship between biphasic shock energy (Joule) and successful cardioversion using anterolateral and anteroposterior self-adhesive patch position. For AL and AP separately, each figure shows risk ratios for restored sinus rhythm between the shock energy level on the horizontal axis and 200 J (as a reference), together with 95% CIs. AL, anterior lateral; AP, anterior–posterior.

Figure 1 shows the risk of bias assessment across trials. Two studies had some concerns, and no study was deemed at high risk of bias. We did not find any indication of small-study effects on either outcome after the first or final shock, although the number of studies was small for interpreting the funnel plots (online supplemental figure 1).

---

### Cardioversion efficacy using pulsed biphasic or biphasic truncated exponential waveforms: a randomized clinical trial [^115ozVKQ]. Journal of the American Heart Association (2017). Low credibility.

In this study, PB shocks were delivered up to the maximal energy output at 200 J allowed by the device. For BTE shocks, the maximum energy output used in this study was 250 J rather than the possible maximum 360 J. This was in order to not disadvantage the PB waveform and to allow a reasonable comparison between the 2 waveforms by maintaining parity in escalating energies between groups. Delivery of the BTE shocks at a maximal energy of 360 J may further increase the cardioversion success rate.

In this study, there was no difference in myocardial injury between waveforms and no changes in hs‐cTnI were observed regardless of waveform and energy used. These findings are in accordance with previous studies, showing no increase in troponin I following cardioversion. 21, 24, 25, 26, 27, 28 In our study, the risk of postshock arrhythmias was low, although we did experience 2 cases of ventricular arrhythmia. The use of a low‐energy escalating protocol is currently recommended for cardioversion, 2, 13 to minimize, eg, postcardioversion arrhythmias. However, a retrospective study reviewing 6398 cardioversion procedures found 5 cases of ventricular fibrillation, in which the energy selection was 50 to 100 J. 29 The risk of inducing ventricular arrhythmia after cardioversion may be increased when using low‐energy shocks close to the defibrillation threshold, which correspond to the upper limit of vulnerability for inducing ventricular fibrillation. 30 Furthermore, a study found a higher first shock success and no increase in postshock arrhythmias when using a fixed high‐energy biphasic shock protocol (200 J) compared with a low‐energy escalating shock protocol (100–150–200 J). 31 Importantly, using higher energy selection for cardioversion may be considered to decrease the risk of induced ventricular arrhythmia, although the optimal shock energy protocol for biphasic cardioversion remains to be identified.

---

### ILCOR scientific knowledge gaps and clinical research priorities for cardiopulmonary resuscitation and emergency cardiovascular care: a consensus statement [^111cEviZ]. Circulation (2018). Medium credibility.

Pediatric defibrillation energy doses — The 2015 CoSTR recommended that the energy dose for defibrillation of pediatric ventricular fibrillation/pulseless ventricular tachycardia should range from 2 to 4 J/kg, monophasic or biphasic, and guidelines differ: the American Heart Association recommends an initial dose of 2 J/kg followed by a second shock of 4 J/kg if needed, whereas the European Resuscitation Council recommends initial and subsequent doses of 4 J/kg; knowledge gaps include the risk/benefits of specific or titrating energy doses in both primary and secondary shockable rhythms.

---

### 2019 ESC guidelines for the management of patients with supraventricular tachycardiaThe task force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC) [^1164ZMMo]. European Heart Journal (2020). High credibility.

Regarding therapeutic procedures for focal atrial tachycardia, more specifically with respect to synchronized electrical cardioversion, ESC 2020 guidelines recommend to perform synchronized direct current cardioversion for acute management of hemodynamically stable patients with FAT if drug therapy fails to convert or control the tachycardia.

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^114fLKUo]. Circulation (2006). Medium credibility.

Direct-current cardioversion — terminology and technical aspects: Direct-current cardioversion involves delivery of an electrical shock synchronized with the intrinsic activity of the heart by sensing the R wave of the ECG to avoid stimulation during the vulnerable phase of the cardiac cycle, and it is used to normalize all abnormal cardiac rhythms except ventricular fibrillation. The term defibrillation implies an asynchronous discharge, which is appropriate for correction of ventricular fibrillation because R-wave synchronization is not feasible, but not for AF. Successful cardioversion of AF depends on the underlying heart disease and the current density delivered to the atrial myocardium, and current may be delivered through external chest wall electrodes or through an internal cardiac electrode; although the latter has been considered superior to external countershocks in obese patients and in patients with obstructive lung disease, it has not been widely applied.

---

### Practice advisory for the perioperative management of patients with cardiac implantable electronic devices: pacemakers and implantable cardioverter-defibrillators 2020: an updated report by the American society of anesthesiologists task force on perioperative management of patients with cardiac implantable electronic devices: erratum [^111MyDiD]. Anesthesiology (2020). High credibility.

Cardiac implantable electronic device (CIED) perioperative management — emergency external defibrillation or cardioversion — details ICD-specific and general measures: before shocks in ICD patients with magnet-disabled therapies, "Before performing emergency defibrillation or cardioversion of the patient with an ICD and magnet-disabled therapies, terminate all sources of EMI and remove the magnet to reenable the ICD's antitachycardia therapies; then observe the patient for the delivery of appropriate antitachycardia therapy from the ICD". If therapies were disabled by programming, "determine whether the antitachycardia therapy should be reenabled"; if function is not restored, "perform emergency external defibrillation or cardioversion when needed". Providers should "Follow ACLS and emergency protocols to provide rapid cardioversion or defibrillation when needed" and "Follow ACLS guidelines for delivered energy level and pad placement". To limit device current flow and optimize pad position, "Attempt to minimize the current flowing through the pulse generator and leads by positioning the defibrillation or cardioversion pads so they are not directly over the CIED", "Use a sternal–posterior rather than anterior–lateral pad positioning whenever possible", and "Use a clinically appropriate energy output regardless of the presence of the CIED". After shocks, "Interrogate the CIED immediately after external cardioversion or defibrillation is performed".

---

### 2023 HRS expert consensus statement on the management of arrhythmias during pregnancy [^112QpavB]. Heart Rhythm (2023). High credibility.

Electrode placement for cardioversion/defibrillation in pregnancy — Defibrillator paddles or electrode pads can be placed in sterno-apical or antero-posterior configurations, and the sterno-apical position is generally recommended for treatment of ventricular arrhythmias, whereas an antero-posterior vector has been proposed for treatment of atrial arrhythmias and can also be used following unsuccessful initial sterno-apical attempts, as it may lead to lower transthoracic impedances; in pregnant patients, special attention should be dedicated to avoiding breast tissue to maximize current delivery to the heart because adipose tissue associated with the breasts may contribute to higher resistance and theoretically decrease the efficacy of the procedure; sterno-apical placement is generally used for cardioversion or defibrillation of ventricular tachycardia and antero-posterior placement is generally used for cardioversion of atrial arrhythmias.

---

### ACC / AHA / ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American college of cardiology / American Heart Association task force and the European Society of Cardiology committee for practice guidelines (writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) [^115AfgJ7]. Journal of the American College of Cardiology (2006). Medium credibility.

Ventricular tachycardia (VT) with pulses — synchronization strategy: Unstable monomorphic VT is treated with synchronized cardioversion, while unstable polymorphic VT is treated as ventricular fibrillation (VF) using high-energy unsynchronized shocks at defibrillation doses. Monomorphic VT in patients with pulses generally responds well to monophasic waveform cardioversion synchronized shocks at initial energies of 100 J or higher. Synchronized cardioversion is generally not recommended to treat unstable polymorphic VT because of unreliable synchronization to a QRS complex, and high-energy unsynchronized shock at defibrillation doses is recommended; if there is any doubt whether monomorphic or polymorphic VT is present in the unstable patient, shock delivery should not be delayed for detailed rhythm analysis.

---

### Cardioversion efficacy using pulsed biphasic or biphasic truncated exponential waveforms: a randomized clinical trial [^112viWM7]. Journal of the American Heart Association (2017). Low credibility.

Introduction

Atrial fibrillation (AF) is the most common cardiac arrhythmia and affects millions of people worldwide. 1 To reduce symptoms and prevent disease progression, direct current cardioversion is a widely used procedure for patients with AF. 2 During the past decades, biphasic waveforms have proven superior to monophasic waveforms for cardioversion of supraventricular tachycardia in several randomized studies. 3, 4, 5, 6 In these studies, more patients were restored to sinus rhythm when receiving biphasic shocks compared with monophasic shocks, using less total delivered energy. Currently, several different biphasic waveforms are available in commercial defibrillators.

Recently, a new pulsed biphasic (PB) waveform was approved for direct current cardioversion and defibrillation. 7 This waveform delivers a chopped modulation of a biphasic truncated exponential (BTE) waveform, where current is rapidly and repeatedly turned on and off. In a nonrandomized clinical study, this PB waveform was found to be more effective in cardioversion of AF or atrial flutter compared with a monophasic waveform. 8 The PB waveform is designed to deliver a high peak and average current at low energy levels, 9, 10 and it is hypothesized that the waveform can deliver high shock efficacy at low energy levels. 7, 11

To date, there are no clinical data on the efficacy of the impedance‐compensated (ie, adjusted to patient's chest impedance) PB waveform, which is currently in use for direct current cardioversion and defibrillation. Lately, international guidelines have identified an important knowledge gap on using the PB waveform, and state that clinical data are warranted. 12 Because the PB waveform has never been compared to other biphasic waveforms in a randomized clinical study, we accordingly aimed to compare the cardioversion efficacy and safety of a PB waveform with a BTE waveform.

---

### Effect of torsemide vs furosemide after discharge on all-cause mortality in heart failure… [^114fu2RA]. JAMA Network (2023). Excellent credibility.

at randomization, systolic blood pressure, estimated glomerular filtration rate categories, diabetes, mineralocorticoid receptor antagonist use at randomization, academic/university hospital, and duration of heart failure. For the primary end point of all-cause mortality, a Cox proportional hazards regression model was used to assess outcome differences between the 2 treatment groups and compute a hazard ratio and 95% CI. Prespecified covariates in the primary model included randomized treatment, age, sex, ejection fraction category, and loop diuretic treatment before index hospital admission. In the subset with reduced ejection fraction heart failure, baseline β-blocker use was 81. 5%, angiotensin-converting enzyme/angiotensin receptor blocker or angiotensin receptor-neprilysin inhibitor use was
67. 5%, mineralocorticoid receptor antagonist use was 44. 3%, and sodium-glucose cotransporter 2 inhibitor use was
7. 8%. Whether other patient populations, such as those diagnosed in the outpatient setting and/or without prior hospitalization, have differential benefit with these therapies was not assessed. Given the uncertainty regarding the correct dose conversion, the protocol allowed flexibility with a 2: 1 to 4: 1 furosemide to torsemide conversion. If the true conversion is closer to 4: 1, it may be that dosing was higher in the torsemide group. Future work will explore different dose conversions and time-varying analyses to better understand the implications of differences in dose. enrolled a high-risk phenotype with a median N-terminal pro–brain natriuretic peptide level of 3913 pg/mL as compared with 4812 pg/mL in the PIONEER-HF trial, 23 2816 pg/mL in the VICTORIA trial, 22 and 1437 pg/mL in the DAPA-HF trial.

24 The high baseline N-terminal pro–brain natriuretic peptide in this study is notable given that the trial included patients with preserved ejection fraction where natriuretic peptide levels are comparatively lower than in reduced ejection fraction.

---

### A national model for developing, implementing, and evaluating evidence-based guidelines for prehospital care [^116e7UYE]. Academic Emergency Medicine (2012). Medium credibility.

Resuscitation — cardiac arrest (VF/VT/Asystole/PEA) defibrillation dosing: The maximum setting on the defibrillator should be used for initial and subsequent defibrillation attempts; defibrillation dosing should follow manufacturer's recommendation in the case of biphasic defibrillators, and if the manufacturer's recommendation is unknown, use highest setting possible. In the case of monophasic devices, the setting should be 360 J (joule) (or 4 J/kg for children).

---

### Electrical energy by electrode placement for cardioversion of atrial fibrillation: a systematic review and meta-analysis [^111JCRWt]. Open Heart (2023). Medium credibility.

Discussion

This comprehensive systematic review that included a meta-analysis and dose–response evaluation presents an up-to-date analysis of RCTs that compared anterolateral versus anteroposterior electrode positioning in cardioversion of AF using biphasic shock and self-adhesive electrodes. The results showed that applied energy levels below 200J were significantly associated with lower chances of success compared with energy applied at 200J, while there was no evidence of differential cardioversion success between energy levels above 200J. We found no substantial differences between the two electrode positions, although with considerable heterogeneity.

Recently, a systematic review with meta-analyses by Nguyen et al examined cardioversion success, electrode position and energy level, respectively. We aimed to examine the relationship between energy level and cumulative cardioversion success. In contrast, Nguyen et al aimed to compare the cumulative cardioversion success between high-energy shocks (minimum 200J) and escalating energy protocols. Our prespecified eligibility criteria focused on trials that randomised electrode placement and that used biphasic shock waves while trials of acute cardioversion or those involving monophasic shockwaves or manual hand-held paddles that no longer reflect standard contemporary practice were not eligible. Our meta-analysis included five randomised trials, none of which overlapped with the four randomised trials selected by Nguyen et al. Nguyen et al reported that high-energy shocks did not significantly improve cumulative cardioversion success compared with an escalating energy protocol. A subgroup analysis suggested a larger effect with anteroposterior pad positioning compared with anteroapical or anterolateral positioning. In contrast, we found a dose–response relationship with increasing levels of energy leading to larger cardioversion success rate up to 200J. Beyond 200J, we found no evidence of improved cardioversion success. Additionally, we found no evidence of difference between anteroposterior and anterolateral pad positioning.

---

### Investigating the efficacy of chest pressure for direct current cardioversion in atrial fibrillation: a randomised control trial protocol (pressure-AF) [^115A61xN]. Open Heart (2021). Medium credibility.

Cardioversion techniques to improve success

Chance of successful cardioversion is directly proportional to cardiac energy delivery. Increased energy delivery heightens the chance of simultaneous depolarisation of all cardiac tissue. There are four major clinician-controlled modifiers that can increase cardiac energy delivery (see table 1). The first is the intensity of energy provided during cardioversion. While other arrythmias require less energy, 50–100 J for atrial flutter, for example, the electrical disorganisation of AF requires higher energies. International guidelines recommend initiating treatment at 150–200 J. The second variable is defibrillator pad position. Anteroposterior pad placement seems to improve success compared with anterolateral positioning. The mechanism may be through increased atrial energy delivery. The third variable is the energy form delivered. Biphasic energy is more effective than monophasic energy and has been consistently shown to improve cardioversion success. The final modifier is the provision of chest pressure during cardioversion. Chest pressure appears efficacious through reducing transthoracic impedance which is inversely proportional to cardiac energy delivery.

Table 1
Clinician-controlled modifiers that increase cardioversion success

Risks of electrical cardioversion

While increasing energy will improve cardioversion success, this is also associated with risk. Moderate to severe post procedural chest pain is reported to occur in 23% of cases and is directly proportional to energy delivery. Cutaneous burns are another significant complication of cardioversion and often associated with high energy shocks. Measures to reduce energy requirements, while maintaining cardioversion efficacy, have the potential benefits of decreasing patient discomfort and reducing burn incidence.

Chest pressure with cardioversion

While chest pressure during cardioversion is reproducible, simple and associated with minimal cost, there is little evidence for its use. Most clinicians still regard close patient contact during cardioversion to be unsafe to the bystander. A systematic review investigating bystander adverse events during defibrillation showed that events were uncommon, always minor and often associated with inappropriate defibrillator use. Moreover, a recent single centre randomised trial involving only 100 patients demonstrated no bystander adverse events with chest pressure during cardioversion. This trial used starting energies of 50 J and found improved cardioversion success, reduced shocks and reduced energy requirements with active compression. There is a clear need for external validity in an adequately powered multicentre randomised trial to examine the utility of routine chest pressure.

---

### The Heart Rhythm Society (HRS) / American society of anesthesiologists (ASA) expert consensus statement on the perioperative management of patients with implantable defibrillators, pacemakers and arrhythmia monitors: facilities and patient management this document was developed as a joint project with the American society of anesthesiologists (ASA), and in collaboration with the American Heart Association (AHA), and the Society of Thoracic Surgeons (STS) [^111AVqk8]. Heart Rhythm (2011). Medium credibility.

Cardioversion in patients with CIEDs — device effects and electrode positioning are summarized as follows: With modern systems, "abnormal function of CIEDs during cardioversion is now rarely observed". In a clinical study "of 44 patients… no CIED malfunction was observed during cardioversion using an anterior-posterior electrode positioned with > 8 cm between the anterior electrode and the CIED", with pads "placed in the anterior-posterior position". On interrogation, "No clinically important problems… were identified during interrogations 1 hour and 1 week after cardioversion", although "a transient decrease in battery impedance and voltage was identified at 1 hour". Adverse interactions have been "noted" with "the anterolateral electrode position", including a case-series "of three patients" where high thresholds developed "several hours to one day… requiring lead revision". After aortic unclamping, "defibrillation energies of 10 to 30 Joules may be applied directly to the ventricles", which has "occasionally… been associated with pulse generator reset".

---

### Energy levels in manual defibrillation after prior AED shock [^114HDLef]. Resuscitation (2025). Medium credibility.

Aim

European guidelines suggest an escalating defibrillation energy protocol for cases of out-of-hospital cardiac arrest (OHCA) with a shockable rhythm. Our regional manual defibrillators are by default set to deliver 200J for the initial shock and 360J for subsequent shocks. In case of a prior AED shock, Emergency Medical Services (EMS) personnel need to deliberately adjust the energy level to 360J before delivering the first shock with their manual defibrillator to adhere to the escalating energy protocol. We investigated adherence to this escalating energy protocol by EMS and the association with clinical outcomes.

Methods

Data were collected from the ARREST-registry in the Netherlands. We analysed OHCA cases in adults with shockable rhythms who had received at least one shock from an AED and from a manual defibrillator. The primary outcome was the adherence to the escalating energy protocol. Secondary outcomes were the relationships of adherence with various clinical outcomes.

Results

In 827 cases, adherence to the escalating energy protocol was 20.3% (95% CI 17.7%-23.2%). No baseline characteristics were significantly associated with increased adherence. Shockable rhythms were terminated by the first manual defibrillator shock in 521/659 (79.1%) cases with 200J and 139/168 (82.7%) cases with 360J (p = 0.33). Overall 30-day survival rate was 38.4%. Adherence to protocol was not significantly associated with differences in clinical outcomes after multivariable analyses.

Conclusion

Adherence to escalating energy protocol by EMS during transition from defibrillation with AED to manual defibrillator is limited. Our data did not provide evidence for a relationship between adherence and clinical outcomes.

---

### Part 6: electrical therapies: automated external defibrillators, defibrillation, cardioversion, and pacing: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care [^1169P3NT]. Circulation (2010). Low credibility.

The recommendations for electrical therapies described in this section are designed to improve survival from SCA and life-threatening arrhythmias. Whenever defibrillation is attempted, rescuers must coordinate high-quality CPR with defibrillation to minimize interruptions in chest compressions and to ensure immediate resumption of chest compressions after shock delivery. The high first-shock efficacy of newer biphasic defibrillators led to the recommendation of single shocks plus immediate CPR instead of 3-shock sequences that were recommended prior to 2005 to treat VF. Further data are needed to refine recommendations for energy levels for defibrillation and cardioversion using biphasic waveforms.

---

### Initial energy setting, outcome and efficiency in direct current cardioversion of atrial fibrillation and flutter [^11648ewe]. Journal of the American College of Cardiology (2001). Low credibility.

Objectives

The purpose of this study was to design a more efficient protocol for the electrical cardioversion of atrial arrhythmias.

Background

Guidelines for electrical cardioversion of atrial arrhythmias recommend starting with low energy shocks, which are often ineffective.

Methods

We recorded the sequence of shocks in 1,838 attempts at cardioversion for atrial fibrillation (AF) and 678 attempts at cardioversion for atrial flutter. These data were used to calculate the probability of success for each shock of a standard series and the probability of success with a single shock at each intensity. In 150 cases, a rhythm strip with the time of each shock allowed us to calculate the time expended on unsuccessful shocks.

Results

We analyzed the effects of 5,152 shocks delivered to patients for AF and 1,238 shocks delivered to patients for atrial flutter. The probability of success on the first shock in AF of > 30 days duration was 5.5% at < 200 J, 35% at 200 J and 56% at 360 J. In atrial flutter, an initial 100 J shock worked in 68%. In AF of > 30 days duration, shocks of < 200 J had a 6.1% probability of success; this fell to 2.2% with a duration > 180 days. In those with AF for > 180 days, the initial use of a 360 J shock was associated with the eventual use of less electrical energy than with an initial shock of ≤ 100 J (581 ± 316 J vs. 758 ± 433 J, p < 0.01, Mann-Whitney U test).

Conclusions

An initial energy setting of ≥ 360 J can achieve cardioversion of AF more efficiently in patients than traditional protocols, particularly with AF of longer duration.

---

### European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), cardiac arrhythmia society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS) [^114E5SxM]. Europace (2019). High credibility.

Sustained monomorphic ventricular tachycardia — patients with sustained ventricular arrhythmias have poorer prognosis and high early and late mortality; the mortality is high, around 50% in hospital and then additionally 10% within 2 years. If feasible, a 12‑lead ECG and atrial electrograms via temporary epicardial wires may help diagnose ventriculo–atrial dissociation (V > A). Immediate cardioversion should be performed for haemodynamically unstable VT without pulse. Electrical cardioversion for stable sustained VT can be used either as first choice or after failed antiarrhythmics, with 150–200 J in biphasic defibrillators, and sedation with short-acting agents should precede energy delivery in awake patients.

---

### 2015 ACC / AHA / HRS guideline for the management of adult patients with supraventricular tachycardia: executive summary: a report of the American college of cardiology / American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society [^116YeX8V]. Circulation (2016). Medium credibility.

Regarding therapeutic procedures for focal atrial tachycardia, more specifically with respect to synchronized electrical cardioversion, ACC/AHA/HRS 2016 guidelines recommend to perform synchronized cardioversion for acute management of hemodynamically unstable patients with FAT.

---

### The low energy safety study (LESS): rationale, design, patient characteristics, and device utilization [^114Ph7Wu]. American Heart Journal (2002). Low credibility.

Background

A 10-J energy safety margin has traditionally been used in programming implantable cardioverter defibrillators (ICDs). The Low Energy Safety Study (LESS) tests the hypothesis that programming shocks to lower energy margins is safe and effective.

Methods

Patients with standard ICD indications undergo defibrillation threshold testing (DFT) at the time of ICD implant, with reconfirmation of lowest successful energy twice (DFT++). Patients are randomized to 2 groups: the first has the initial 2 shocks for ventricular fibrillation conversion programmed at 2 energy steps above DFT++ (typically 4–6 J, maximum 10 J) with subsequent shocks at maximum energy, and the second has all shocks programmed at maximum energy. Patients are followed up every 3 months for 2 years to assess shock conversion efficacy of spontaneous arrhythmias. In a subgroup of patients, there is a second randomization to energy levels of 0, 1, 2, 3, or 4 steps above implant DFT++ for conversion testing of 3 induced ventricular fibrillation episodes at prehospital discharge, 3 months, and 12 months after implant.

Results

Enrollment is complete (702 patients), but follow-up results are pending. There were no significant variations in implant indications and baseline antiarrhythmic drug use over the 3-year enrollment period, although an increase in the percentage of dual-chamber ICDs implanted occurred, with the majority (65%) of implanted ICDs being dual-chamber devices by the end of the enrollment period.

Conclusion

The results of LESS should facilitate the development of algorithms for programming ICD energy safety margins.

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^112rC6mY]. Circulation (2024). High credibility.

Electrical cardioversion for atrial fibrillation (AF) — key recommendations are as follows: In patients with hemodynamic instability attributable to AF, immediate electrical cardioversion should be performed to restore sinus rhythm. In patients with AF who are hemodynamically stable, electrical cardioversion can be performed as an initial rhythm-control strategy or after unsuccessful pharmacological cardioversion. In patients with AF undergoing electrical cardioversion, energy delivery should be synchronized to the QRS to reduce the risk of inducing ventricular fibrillation (VF). For elective electrical cardioversion in AF, use of biphasic energy of at least 200 J as initial energy can be beneficial to improve success of the initial electrical shock. When AF duration is longer or the initial shock is unsuccessful during elective cardioversion, optimization of electrode vector, use of higher energy, and pretreatment with antiarrhythmic drugs can facilitate success. In patients with obesity and AF, manual pressure augmentation and/or further escalation of electrical energy may be beneficial to improve success of electrical cardioversion.

---

### Cardioversion efficacy using pulsed biphasic or biphasic truncated exponential waveforms: a randomized clinical trial [^111TTKiC]. Journal of the American Heart Association (2017). Low credibility.

Conclusions

This study demonstrated that when compared by energy levels, cardioversion using a BTE waveform was more effective compared to a PB waveform. There was no difference in myocardial injury between the 2 waveforms (ie, changes in troponin I levels).

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^117T33v4]. Circulation (2024). High credibility.

Electrical and pharmacologic cardioversion — section headers indicate the topics covered include cardioversion strategies and prevention of thromboembolism associated with cardioversion, labeled as "Electrical and Pharmacologic Cardioversion" and "Prevention of Thromboembolism in the Setting of Cardioversion".

---

### Part 9: adult advanced life support: 2025 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care [^116oYhfH]. Circulation (2025). High credibility.

Regarding medical management for cardiac arrest, more specifically with respect to management of AF/atrial flutter, cardioversion, AHA 2025 guidelines recommend to consider using an initial energy setting of at least 200 J for synchronized cardioversion of AF in adults with any currently US-approved biphasic waveform defibrillator, and increment the energy in the event of shock failure, depending on the biphasic defibrillator used.

---

### The 2020 Canadian Cardiovascular Society / Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation [^113bax4P]. The Canadian Journal of Cardiology (2020). High credibility.

Regarding medical management for atrial fibrillation, more specifically with respect to rhythm control, electrical cardioversion, CCS/CHRS 2020 guidelines recommend to use at least a 150-J biphasic waveform as the initial energy setting for direct current cardioversion.

---

### Monophasic and biphasic shock for transthoracic conversion of atrial fibrillation: systematic review and network meta-analysis [^117WuxLt]. Resuscitation (2016). Low credibility.

Objectives

Conduct a systematic review of the literature to compare the efficacy of different biphasic and monophasic shock waveforms technologies for transthoracic cardioversion of Atrial Fibrillation (AF).

Methods

We searched PubMed, EMBASE, The Cochrane Library, LILACS and ClinicalTrials.gov databases for randomized clinical trials comparing two or more defibrillation waveforms when performing elective transthoracic cardioversion of AF. The outcomes assessed were 1st shock success, overall success, cumulative energy and number of shocks to restore Normal Sinus Rhythm.

Results

Were included 23 trials involving 3046 patients, 5 biphasic and the monophasic waveform. Direct meta-analysis revealed that Biphasic waveforms have higher chance to achieve cardioversion in the 1st shock (OR: 3.2; 95% CI 2.2–4.7) and after a sequence of attempts (OR:2.4; 95% CI 1.5–3.9), requiring 296 less Joules (95% CI 356–237) and 0.74 less shocks (95%CI 1.03–0.44) when compared to Monophasic. Network meta-analysis showed no significant differences between the Biphasic technologies of PhysioControl ADAPTIV, Philips SMART and ZOLL Rectilinear, in any of the four outcomes.

Conclusion

The evidences points to a Biphasic waveform superiority over Monophasic to perform AF cardioversion, supporting current guidelines to use less energy when using a Biphasic defibrillator. It is suggested that the Biphasic defibrillators from PhysioControl ADAPTIV, Philips SMART and ZOLL Rectilinear have similar efficacy and the use of any of them may result in similar chances, energy and number of shocks to achieve successful AF cardioversion.

---

### ACC / AHA / ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American college of cardiology / American Heart Association task force and the European Society of Cardiology committee for practice guidelines (writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) [^111W1t6o]. Journal of the American College of Cardiology (2006). Medium credibility.

Acute heart failure arrhythmia management — supraventricular rhythm control — notes that given its relatively rapid onset of action and superior safety profile in HF, intravenous amiodarone for life-threatening arrhythmias during acute HF has gained widespread acceptance, and in acutely ill HF, supraventricular tachycardia (SVT) and atrial fibrillation (AF) or atrial flutter may impose hemodynamic decompensation requiring aggressive therapy; poorly tolerated SVT may be better treated acutely by synchronous cardioversion at relatively low energies (e.g., 50 to 100 J biphasic), verapamil may be effective for recurrent AV node–dependent SVTs but care should be taken due to negative inotropic effects, and intravenous amiodarone may be more effective at rate control of AF or atrial flutter and may restore sinus rhythm; in HF, amiodarone alone or with electrical cardioversion is effective at slowing the heart rate and achieving cardioversion, and for unstable arrhythmia cardioversion is appropriate with amiodarone preferred for longer-term administration and generally well tolerated hemodynamically.

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^114z1UZd]. Circulation (2024). High credibility.

Atrial fibrillation — electrical and pharmacological cardioversion overview is described as follows: Cardioversion to restore sinus rhythm is a mode of acute rhythm control and can be achieved electrically or pharmacologically. Electrical cardioversion, given rapidity and efficacy, is the treatment of choice for patients with hemodynamic instability attributable to AF, and cardioversion should also be considered for hemodynamically stable AF intolerant of atrioventricular dyssynchrony, loss of atrial kick, or unable to achieve adequate rate control. In stable AF, both electrical and pharmacological cardioversion are acceptable, safe, and efficacious; electrical cardioversion is more effective than pharmacological cardioversion alone but involves the trade-off of anesthesia or sedation. Thromboembolic risks and considerations for anticoagulation apply to both pharmacological and electrical cardioversion.

---

### Electrical energy by electrode placement for cardioversion of atrial fibrillation: a systematic review and meta-analysis [^116USCst]. Open Heart (2023). Medium credibility.

Limitations

This meta-analysis included five relatively small studies and has, therefore, limited statistical power and precision. There was considerable clinical diversity across studies, which resulted in large statistical heterogeneity. Studies were non-blinded, and outcome assessment was blinded in only one study. Results from our dose–response analyses should be interpreted with caution given the risk of ecological bias and considerable clinical diversity across studies. Moreover, we made the assumption that success at a lower energy level would have been observed at a higher energy level.

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^114GSigG]. Circulation (2006). Medium credibility.

Atrial fibrillation (AF) direct-current cardioversion — biomarker and electrocardiographic changes: Transient ST-segment elevation may appear on the electrocardiogram after cardioversion, and in a study of 72 cardioversion attempts with average energy over 400 J (range 50 to 1280 J), serum troponin-T and troponin-I levels did not rise significantly; microscopic myocardial damage related to direct-current cardioversion has not been confirmed and is probably clinically insignificant.

---

### Survival to hospital discharge with biphasic fixed 360 joules versus 200 escalating to 360 joules defibrillation strategies in out-of-hospital cardiac arrest of presumed cardiac etiology [^116PnXFo]. Resuscitation (2019). Medium credibility.

Introduction

Guidelines recommend constant or escalating energy levels for shocks after the initial defibrillation attempt. Studies comparing survival to hospital discharge with escalating vs fixed high energy level shocks are lacking. We compared survival to hospital discharge for 200J escalating to 360J vs fixed 360J in patients with initial ventricular fibrillation/pulseless ventricular tachycardia in a post-hoc analysis of the Circulation Improving Resuscitation Care trial database.

Methods and Results

Pre-shock rhythm, rhythm 5s after shock, shock energy levels, termination of ventricular fibrillation/pulseless ventricular tachycardia (TOF), and survival to hospital discharge were recorded. Association between defibrillation strategy and survival to hospital discharge was investigated with multivariable logistic regression. The escalating energy group included 260 patients and 883 shocks vs 478 patients and 1736 shocks in the fixed-high energy group. There was no difference in survival to hospital discharge between escalating (70/255 patients, 28%) and fixed energy group (132/478 patients, 28%) (unadjusted OR 1.00, 95% CI 0.72–1.42 and adjusted OR 0.81, 95% CI 0.54–1.22, p = 0.32). First shock TOF was 86% in the escalating group compared to 83% in the fixed-high group, p = 0.27.

Conclusion

There was no difference in survival to hospital discharge or the frequency of TOF between escalating energy and fixed-high energy group. ClinicalTrials.gov Identifier: NCT00597207.

---

### Investigating the efficacy of chest pressure for direct current cardioversion in atrial fibrillation: a randomised control trial protocol (pressure-AF) [^115GzVLC]. Open Heart (2021). Medium credibility.

Methods and analysis

Trial design

This will be a prospective multicentre randomised control trial located in Australia. Patients and statistical analysis will be blinded. Inclusion criteria are age over 18 years, AF referred for cardioversion and 3 weeks of therapeutic anticoagulation or transoesophageal echocardiography excluding left atrial appendage thrombus (see box 1). Exclusion criteria are other atrial arrhythmias (atrial flutter or atrial tachycardia), those who are pregnant or breast feeding and medical comorbidity where anticoagulation is contraindicated. Definition of successful cardioversion will be sinus rhythm at 1 min after shock to maintain consistency with other studies. Patients will be randomised via an online tool in a 1:1 ratio to control and interventional arms.

Box 1
Eligibility criteria

Inclusion criteria

Age over 18 years of age.
Ability to provide written informed consent.
Atrial fibrillation referred for cardioversion.
Three weeks of therapeutic anticoagulation.
Transesophageal echocardiography excluding left atrial appendage thrombus.

Exclusion criteria

Other atrial arrhythmias (atrial tachycardia, atrial flutter).
Pregnant or breast feeding.
Medical comorbidity where anticoagulation is contraindicated.

Cardioversion technique

Anteroposterior placement of self-adhesive pads with biphasic energy will be provided to all patients. Sedation will be performed by an anaesthetist with a recommended anaesthetic regime of weight-based dosing of propofol ± midazolam titrated to effect. Direct chest pressure will be provided on the anterior defibrillator pad with plastic gloves and a folded towel (see figure 1). Estimated chest pressure provision was assessed among cardiology advanced trainees at the centres involved. Four trainees provided 36 applications of blinded simulated chest pressure on weight scales with mean pressure of 25.5 ± 2.6 kg.

Figure 1
Diagram of cardioversion technique.

The control arm will receive four sequential shocks until cardioversion success with energies of 150, 200, 360 and 360 J. Chest pressure will be provided with the final shock if the arrhythmia is refractory to the first three defibrillations. The interventional arm will receive chest pressure from the first shock with the same energies. Both arms will receive maximal energy with chest pressure (figure 2).

Figure 2
Day of cardioversion: study flow diagram.

Primary and secondary endpoints

The primary efficacy endpoint will be total joules provided during the cardioversion encounter. Secondary efficacy endpoints will be success of first shock for reversion to sinus rhythm, transthoracic impedance at the time of shock and sinus rhythm at post cardioversion ECG (30 min after). Safety and tolerability endpoints will be patient chest pain post cardioversion (Ordinal Scale 0–10) and incidence of shock delivered to proceduralist.

---

### Anteriolateral versus anterior-posterior electrodes in external cardioversion of atrial fibrillation: a systematic review and meta-analysis of clinical trials [^114CWXtZ]. Clinical Cardiology (2023). Medium credibility.

Moreover, the progression of A.fib is associated with poor outcomes after transcutaneous ablation. Surprisingly, our analysis reports better efficacy of anterior–lateral electrode positioning in patients with LA enlargement with a diameter greater than 45 mm when compared to anterior–posterior positioning. Additionally, the anterior–lateral position is associated with higher success rates in patients receiving less than five shocks. This denotes the superiority of the anterior–lateral position in managing this hard‐to‐treat subset of the A.fib population.

Second, a divergent patient population seems to be a valid prognostication factor in determining the safety and efficacy of various approaches. Our pooled analysis revealed that anterior–lateral position is more likely to attain higher success chances in patients aged 60 years old or more.

Third, it is essential to consider that some medical practices have been recently obsolete and are no longer clinical guidelines. One is the use of monophasic shocks in cardioversion which have been widely replaced with biphasic shocks that have shown optimal efficacy in managing different types of arrhythmias. While Kirchhof et al. have used monophasic shocks and concluded more favored outcomes with the anterior–posterior approach, other randomized trials that have also utilized monophasic shocks showed no differing outcomes in either approach. Standardized hand‐held steel paddles are associated with less intrathoracic impedance with a subsequent increase in intra‐thoracic shock field gradient compared to self‐adhesive electrodes. It is recommended to apply pressure on anterior–lateral electrodes for higher efficacy.

Given the current data, it is reasonable to consider the anterior–lateral position as a first‐line modality in AF cardioversion, given the relatively higher success rates, especially in elderly patients and those with enlarged left atrium indicating LA remodeling. Additionally, the anterior–lateral position has anatomical convenience and easier accessibility, particularly in critically ill patients.

Nevertheless, our study has some limitations. Variable protocols for cardioversion have been applied. While some papers followed the step‐up energy levels approach, others used initial high‐energy levels of 200 J and higher on failed attempts. We found some bias in deviation from the intended interventions, missing outcome data, and measurement of the outcome domains in some studies; however, we found no significant bias in the randomization process domain in the included studies. Lastly, our included articles had variable proportions of persistent and permanent AF, which are hard to treat and might alter the outcomes.

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^1113Lbbc]. Circulation (2006). Medium credibility.

Pharmacological versus electrical cardioversion — effectiveness, timing, and anticoagulation considerations: Cardioversion may be achieved by means of drugs or electrical shocks, and although drug use has increased, disadvantages include the risk of drug-induced torsades de pointes; pharmacological cardioversion is less effective than direct-current cardioversion when biphasic shocks are used, while electrical cardioversion requires conscious sedation or anesthesia. There is no evidence that the risk of thromboembolism or stroke differs between pharmacological and electrical methods, and recommendations for anticoagulation are therefore the same for both methods. Pharmacological cardioversion seems most effective when initiated within 7 d after the onset of an episode of atrial fibrillation; a large proportion of patients with recent-onset atrial fibrillation experience spontaneous cardioversion within 24 to 48 h, whereas spontaneous conversion is less frequent with longer than 7-d duration and efficacy of drug cardioversion is markedly reduced. Pharmacological therapy may accelerate restoration of sinus rhythm but the advantage over placebo is modest after 24 to 48 h and is much less effective in persistent atrial fibrillation, and some drugs have a delayed onset with conversion not occurring for several days after initiation. Antiarrhythmic drugs can interact with vitamin K antagonist oral anticoagulants when added or withdrawn, and when anticoagulation is initiated for elective cardioversion, adding an antiarrhythmic may perturb the intensity of anticoagulation beyond the intended therapeutic range, raising the risk of bleeding or thromboembolic complications.

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^1131VJkV]. Circulation (2024). High credibility.

Recommendation-specific supportive text — "No studies compare the efficacy of electrical cardioversion with that of pharmacological cardioversion in patients with AF who are hemodynamically unstable".

---

### Maximum-fixed energy shocks for cardioverting atrial fibrillation [^1141gxVU]. European Heart Journal (2020). Medium credibility.

Aims

Direct-current cardioversion is one of the most commonly performed procedures in cardiology. Low-escalating energy shocks are common practice but the optimal energy selection is unknown. We compared maximum-fixed and low-escalating energy shocks for cardioverting atrial fibrillation.

Methods and Results

In a single-centre, single-blinded, randomized trial, we allocated elective atrial fibrillation patients to cardioversion using maximum-fixed (360–360–360J) or low-escalating (125–150–200J) biphasic truncated exponential shocks. The primary endpoint was sinus rhythm 1 min after cardioversion. Safety endpoints were any arrhythmia, myocardial injury, skin burns, and patient-reported pain after cardioversion. We randomized 276 patients, and baseline characteristics were well-balanced between groups (mean ± standard deviation age: 68 ± 9years, male: 72%, atrial fibrillation duration > 1 year: 30%). Sinus rhythm 1 min after cardioversion was achieved in 114 of 129 patients (88%) in the maximum-fixed energy group, and in 97 of 147 patients (66%) in the low-escalating energy group (between-group difference; 22 percentage points, 95% confidence interval 13–32, P < 0.001). Sinus rhythm after first shock occurred in 97 of 129 patients (75%) in the maximum-fixed energy group compared to 50 of 147 patients (34%) in the low-escalating energy group (between-group difference; 41 percentage points, 95% confidence interval 30–51). There was no significant difference between groups in any safety endpoint.

Conclusion

Maximum-fixed energy shocks were more effective compared with low-escalating energy shocks for cardioverting atrial fibrillation. We found no difference in any safety endpoint.

---

### Efficacy of transthoracic cardioversion of atrial fibrillation using a biphasic, truncated exponential shock waveform at variable initial shock energies [^111JcPpY]. The American Journal of Cardiology (2004). Low credibility.

Biphasic shocks are more effective than damped sine wave monophasic shocks for transthoracic cardioversion (CV) of atrial fibrillation (AF), but the optimal protocol for CV with biphasic shocks has not been defined. We conducted a prospective, randomized study of 120 consecutive patients with persistent AF to delineate the dose-response curve for CV of AF with a biphasic truncated exponential shock waveform and to identify clinical predictors of shock efficacy. Our data suggest that the initial shock energy for CV with this waveform should be 200 J if the patient weighs < 90 kg and 360 J if the patient weighs ≥ 90 kg.

---

### ACC / AHA / ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American college of cardiology / American Heart Association task force and the European Society of Cardiology committee for practice guidelines (writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) [^111hd824]. Journal of the American College of Cardiology (2006). Medium credibility.

Defibrillation energy dosing and post-shock actions: The initial recommended shock energy with a biphasic defibrillator is 150 to 200 J (use recommended device-specific dose; in absence of a recommended dose, 200 J should be used) and an equal or higher dose is recommended for second and subsequent shocks; if a monophasic defibrillator is used, 360 J is used for all shocks. Lower energy levels should not be used for unsynchronized shocks because they can provoke VF when given in an unsynchronized mode. After shock delivery, the health care provider should be prepared to provide immediate CPR and follow the advanced cardiac life support (ACLS) pulseless arrest algorithm if pulseless arrest develops. While 3 successive ("stacked") shocks were recommended in the previous version of the ECC guidelines, a 1-shock strategy is now recommended to minimize time between chest compressions and shock delivery and resumption of chest compressions. Epinephrine, 1 mg intravenously, is administered and followed by repeated defibrillation attempts at 360 J.

---

### Cardioversion efficacy using pulsed biphasic or biphasic truncated exponential waveforms: a randomized clinical trial [^1178No9T]. Journal of the American Heart Association (2017). Low credibility.

Background

Several different defibrillators are currently used for cardioversion and defibrillation of cardiac arrhythmias. The efficacy of a novel pulsed biphasic (PB) waveform has not been compared to other biphasic waveforms. Accordingly, this study aims to compare the efficacy and safety of PB shocks with biphasic truncated exponential (BTE) shocks in patients undergoing cardioversion of atrial fibrillation or -flutter.

Methods and Results

This prospective, randomized study included patients admitted for elective direct current cardioversion. Patients were randomized to receive cardioversion using either PB or BTE shocks. We used escalating shocks until sinus rhythm was obtained or to a maximum of 4 shocks. Patients randomized to PB shocks received 90, 120, 150, and 200 J and patients randomized to BTE shocks received 100, 150, 200, and 250 J, as recommended by the manufacturers. In total, 69 patients (51%) received PB shocks and 65 patients (49%) BTE shocks. Successful cardioversion, defined as sinus rhythm 4 hours after cardioversion, was achieved in 43 patients (62%) using PB shocks and in 56 patients (86%) using BTE shocks; ratio 1.4 (95% CI 1.1–1.7) (P = 0.002). There was no difference in safety (ie, myocardial injury judged by changes in high-sensitive troponin I levels; ratio 1.1) (95% CI 1.0–1.3), P = 0.15. The study was terminated prematurely because of an adverse event.

Conclusions

Cardioversion using a BTE waveform was more effective when compared with a PB waveform. There was no difference in safety between the 2 waveforms, as judged by changes in troponin I levels.

Clinical Trial Registration

URL: http://www.clinicaltrials.gov. Unique identifier: NCT02317029.

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^115fTtkM]. Circulation (2006). Medium credibility.

Internal atrial defibrillators — A transvenous atrial cardioverter delivering a 3/3-ms biphasic waveform shock required relatively high energy in persistent atrial fibrillation (mean 3.5 J). An implantable device with atrial sensing/cardioversion and ventricular sensing/pacing was evaluated in 290 patients with mean left ventricular ejection fraction greater than 50% who had not responded to 4 antiarrhythmic drugs; across 614 AF episodes treated with 1497 shocks (mean 2.4 shocks per episode), conversion to sinus rhythm was 93%. These units accurately record AF and provide valuable measurement of AF control, but patient tolerability limits routine use because most patients find discharge energies over 1 J uncomfortable and the mean cardioversion threshold is approximately 3 J, making such devices unacceptable for routine clinical use.

---

### Part 9: adult advanced life support: 2025 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care [^111Qtiif]. Circulation (2025). High credibility.

Regarding medical management for cardiac arrest, more specifically with respect to management of AF/atrial flutter, cardioversion, AHA 2025 guidelines recommend to recognize that the usefulness of double synchronized cardioversion as a rescue treatment for shock-refractory AF in adults is uncertain.

---

### Electrical energy by electrode placement for cardioversion of atrial fibrillation: a systematic review and meta-analysis [^113jBd4k]. Open Heart (2023). Medium credibility.

Objective

Electrode patch position may not be critical for success when cardioverting atrial fibrillation (AF), but the relevance of applied electrical energy is unclarified. Our objective was to perform a meta-analysis of randomised trials to examine the dose–response relation between energy level and cardioversion success by electrode position in elective cardioversion.

Methods

We searched PubMed, Embase, The Cochrane Library, Google Scholar and Scopus Citations. Inclusion criteria were randomised controlled trials using biphasic shock waves and self-adhesive patches, and publication date from 2000 to 2023. We used random-effects dose-response models to meta-analyse the relation between energy level and cardioversion success by anterolateral and anteroposterior position. Random-effects models estimated pooled risk ratios (RR) for cardioversion success after the first and the final shocks between the two electrode positions.

Results

We included five randomised controlled trials (N = 1078). After the first low-energy shock, the electrode position was not significantly associated with the likelihood of successful cardioversion (pooled RR anterolateral vs anteroposterior placement 1.28, 95% CI 0.93 to 1.76, with considerable heterogeneity). After a high-energy final shock, there was no evidence of an association between the electrode position and the cumulative chance of cardioversion success (pooled RR anterolateral vs anteroposterior 1.05, 95% CI 0.97 to 1.14). Regardless of electrode position, cardioversion success was significantly less likely with shock energy levels < 200J compared with 200J.

Conclusion

Evidence from contemporary randomised trials suggests that higher level of electrical energy is associated with higher conversion rate when cardioverting AF with a biphasic shockwave. Positioning of electrodes can be based on convenience.

---

### Impact of defibrillator electrode placement on outcome of electrical cardioversion of atrial fibrillation: a pilot observational study [^112ZyUzC]. Journal of the American Heart Association (2024). Medium credibility.

Clinical Perspective

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is increasing in prevalence, especially as the population ages. Current reports estimate the overall prevalence of AF in the United States to be around 1% to 2% of the population with numbers projected to reach up to 16 million adults by 2050. Electrical cardioversion is frequently used to restore sinus rhythm in patients with AF. However, it can be unsuccessful in up to 12% of patients. Optimizing the efficiency of electrical current delivery to the atria during cardioversion should improve procedure efficacy and reduce the need to employ high‐energy shocks for success.

Current guidelines offer minimal procedural guidance on methods to maximize cardioversion success rates. Current European and American guidelines recommend positioning the cardioversion electrode in the anterior–posterior configuration. However, these recommendations were primarily derived from prior studies using monophasic defibrillators, which are rarely used in present‐day clinical practice. Second, the optimal starting energy for biphasic defibrillators has not been defined with studies using varying energies ranging from 100 to 360 J. Indeed, modern guidelines and consensus statements do not provide specific recommendations on either the starting energy level or energy escalation strategies when using biphasic defibrillators for AF cardioversion. In cases of cardioversion failure, reattempting cardioversion with different electrode positioning (switching between anterior–posterior and anterior–lateral), energy escalation and application of external pressure on cardioversion electrode pads have been suggested.

Despite a wide range of body habitus among patients, cardioversion electrode placement is performed by nursing and technical personnel on the basis of empiric positioning without landmark guidance. We hypothesized that cardioversion failure or requirements for higher energy delivery for successful electrical cardioversion of AF could in part be attributable to suboptimal defibrillator electrode positioning relative to the anatomic position of the heart.

---

### Cardioversion efficacy using pulsed biphasic or biphasic truncated exponential waveforms: a randomized clinical trial [^111EEQiD]. Journal of the American Heart Association (2017). Low credibility.

Cardioversion Protocol

Cardioversion shocks were provided until sinus rhythm was restored or to a maximum of 4 shocks. The patients randomized to PB shocks received 90, 120, 150, and 200 J, and the patients randomized to BTE shocks received 100, 150, 200, and 250 J. We used these escalating shock protocols based on manufacturer's recommended settings.

Anesthesia was provided in a standardized fashion to patients using 1 mg intravenous propofol per kilogram body weight to a maximum dose of patient's height in centimeters minus 100 cm. Subsequent boluses of 20 mg were administered as required. During the procedure, patients were treated with either oxygen or room air to maintain oxygen saturations of 94% to 98%.

We used the defibrillator‐specific self‐adhesive wet polymer gel pads. All shocks were delivered unblinded using an anterior–posterior pad position. 14 The anterior pad was applied to the left of the sternum with the pad centrum at third intercostal space. The posterior pad was placed with the pad edge laterally to the spinal column on the lower part of the scapula. The defibrillators were switched to "R" wave synchronized mode.

One minute after last shock delivery and after 30 minutes, the cardiac rhythm was documented by obtaining a 12‐lead ECG. After 4 hours with continuous cardiac telemetric surveillance, another 12‐lead ECG was recorded.

Blood Sampling and Biochemical Analysis

Blood samples were drawn from a venous catheter into lithium heparin tubes and centrifuged immediately at 344 g for 15 minutes. High‐sensitive cardiac troponin I (hs‐cTnI) was analyzed in a DANAK ISO 15189 accredited laboratory using ARCHITECT STAT hs‐cTnI assay (Abbott Laboratories, Abbott Park, IL). The coefficient of variation was maximum 10% at the limit of quantification (10 ng/L).

---

### Anterior-lateral versus anterior-posterior electrode position for cardioverting atrial fibrillation [^1171sZvu]. Circulation (2021). Medium credibility.

Background

Smaller randomized studies have reported conflicting results regarding the optimal electrode position for cardioverting atrial fibrillation. However, anterior-posterior electrode positioning is widely used as a standard and believed to be superior to anterior-lateral electrode positioning. Therefore, we aimed to compare anterior-lateral and anterior-posterior electrode positioning for cardioverting atrial fibrillation in a multicenter randomized trial.

Methods

In this multicenter, investigator-initiated, open-label trial, we randomly assigned patients with atrial fibrillation scheduled for elective cardioversion to either anterior-lateral or anterior-posterior electrode positioning. The primary outcome was the proportion of patients in sinus rhythm after the first shock. The secondary outcome was the proportion of patients in sinus rhythm after up to 4 shocks escalating to maximum energy. Safety outcomes were any cases of arrhythmia during or after cardioversion, skin redness, and patient-reported periprocedural pain.

Results

We randomized 468 patients. The primary outcome occurred in 126 patients (54%) assigned to the anterior-lateral electrode position and in 77 patients (33%) assigned to the anterior-posterior electrode position (risk difference, 22 percentage points [95% CI, 13–30]; P < 0.001). The number of patients in sinus rhythm after the final cardioversion shock was 216 (93%) assigned to anterior-lateral electrode positioning and 200 (85%) assigned to anterior-posterior electrode positioning (risk difference, 7 percentage points [95% CI, 2–12]). There were no significant differences between groups in any safety outcomes.

Conclusions

Anterior-lateral electrode positioning was more effective than anterior-posterior electrode positioning for biphasic cardioversion of atrial fibrillation. There were no significant differences in any safety outcome. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03817372.

---

### Electrical energy by electrode placement for cardioversion of atrial fibrillation: a systematic review and meta-analysis [^115vvJWv]. Open Heart (2023). Medium credibility.

Results

Literature search

Online supplemental figure 1 shows the flow of study selection. The initial search yielded 331 results. We retrieved 10 full-text records of which five studies were excluded because of monophasic shock use and/or use of hand-held defibrillator paddles. We included five RCTs, with a total of 1078 patients. Of the patients, 547 were allocated to the AL electrode placement, and 531 patients were allocated to the anterior–posterior electrode placement.

Trial and baseline patient characteristics

The five trials included 'recent-onset' (AF present < 48 hours) or persistent AF. The mean age of participants ranged from 55 to 69 years, the proportion of men ranged from 63% to 82.5%, and the prevalence of hypertension from 32% to 64.5% (table 2).

Table 2
Baseline characteristics of study populations in included trials

The trials used different step-up protocols with sequential shocks of increasing energy (tables 1 and 3). Two trials included a cross-over shock with high energy. The anterior–posterior electrode position differed between trials, with some placing the electrodes in the left infraclavicular and left infrascapular region, while others used the right infraclavicular and left infrascapular region, and one trial placed the electrodes in the midsternal and interscapular region.

Table 3
Dose–response evaluation of cumulated cardioversion proportion of biphasic electrical cardioversion of atrial fibrillation using self-adhesive patches in anterolateral versus anteroposterior positions

In all RCTs, clinicians and patients were not blinded, and only one study used blinded adjudication of the outcome. The outcome definition differed between trials, one trial defined successful cardioversion as two consecutive P waves within 1 min after the procedure, another trial defined cardioversion as restoration of sinus rhythm for a least 30 s, one trial defined success as at least one clearly visible P wave within 30 s after the shock, and another trial defined the outcome as sinus rhythm 1 min after the final shock. One trial did not specify the time window for the adjudication of successful cardioversion.

---

### Part 9: adult advanced life support: 2025 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care [^111HFnMD]. Circulation (2025). High credibility.

Regarding medical management for cardiac arrest, more specifically with respect to management of AF/atrial flutter, cardioversion, AHA 2025 guidelines recommend to consider using an initial energy setting of 200 J for synchronized cardioversion of atrial flutter in adults, and increment the energy in the event of shock failure, depending on the biphasic defibrillator used.

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^112ZEmH6]. Circulation (2006). Medium credibility.

Direct-current cardioversion of atrial fibrillation and flutter — recommendations: When a rapid ventricular response does not respond promptly to pharmacological measures in AF with ongoing myocardial ischemia, symptomatic hypotension, angina, or HF, immediate R-wave synchronized direct-current cardioversion is recommended (Level of Evidence: C). Immediate direct-current cardioversion is recommended for AF with preexcitation when very rapid tachycardia or hemodynamic instability occurs (Level of Evidence: B). Cardioversion is recommended in patients without hemodynamic instability when AF symptoms are unacceptable, and in case of early relapse after cardioversion, repeated direct-current attempts may be made following administration of antiarrhythmic medication (Level of Evidence: C). As Class IIa, direct-current cardioversion can be useful to restore sinus rhythm as part of a long-term management strategy in AF (Level of Evidence: B), and patient preference is a reasonable consideration for infrequently repeated cardioversions in symptomatic or recurrent AF (Level of Evidence: C). As Class III, frequent repetition of direct-current cardioversion is not recommended when periods of sinus rhythm are relatively short after multiple procedures despite prophylactic antiarrhythmic drug therapy (Level of Evidence: C), and electrical cardioversion is contraindicated in patients with digitalis toxicity or hypokalemia (Level of Evidence: C).

---

### 2015 ACC / AHA / HRS advanced training statement on clinical cardiac electrophysiology (A revision of the ACC / AHA 2006 update of the clinical competence statement on invasive electrophysiology studies, catheter ablation, and cardioversion) [^113JgpcD]. Heart Rhythm (2016). Medium credibility.

ACC/AHA/HRS advanced training — other supraventricular tachycardias medical knowledge includes knowing the pathophysiological basis of atrial tachycardia, junctional tachycardia, atrioventricular nodal re-entrant tachycardia, and accessory pathway-mediated tachycardia and associated risks including sudden cardiac death, heart failure, and stroke; knowing methods to stratify risk of sudden death in patients with pre-excitation; knowing methods to diagnose these tachycardias; knowing when and the methods to recommend drug therapy for these patients; and knowing the indications for, techniques of, and complications associated with catheter ablation for treatment of these tachycardias, with milestone level III indicated for each.

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^115urU5B]. Circulation (2024). High credibility.

Regarding medical management for atrial fibrillation, more specifically with respect to rhythm control, electrical cardioversion, ACC/ACCP/AHA/HRS 2024 guidelines recommend to consider using manual pressure augmentation and/or further escalation of electrical energy to improve the success of electrical cardioversion in patients with AF and obesity.

---

### Characteristics and outcomes of recipients of heart transplant with coronavirus disease 2019… [^114KaFCs]. JAMA Network (2020). Excellent credibility.

Comorbid conditions included hypertension in 20 patients, diabetes in 17 patients, and cardiac allograft vasculopathy in 16 patients. Twenty-two participants were admitted for treatment, and 7 required mechanical ventilation. In this article, we present a large case series of recipients of HT with COVID-19 and describe their presentation, disease course, outcomes, and immunosuppression management. The aim of this case series is to describe the outcomes of recipients of HT who are chronically immunosuppressed and develop COVID-19 and raise important questions about the role of the immune system in the disease process.

Twenty patients had hypertension, 17 of 28 had diabetes mellitus, 7 of 28 were obese, 10 of 28 had stage IV or greater chronic kidney disease, 16 of 28 had cardiac allograft vasculopathy, and 4 of 28 had preexisting allograft dysfunction. Evidence of myocardial injury was present in 13 patients, and the median peak high-sensitivity troponin T level was 0. 055 nanograms per milliliter. Inflammatory parameters were markedly elevated, in that high-sensitivity C-reactive protein was greater than normal in all patients, with a median peak of 11. 83 milligrams per deciliter; interleukin 6 was elevated in 15 patients, with a median peak of 105 picograms per milliliter; and D-dimer was greater than 1 microgram per milliliter in 14 patients. Seven patients had an echocardiogram during hospitalization. When compared with the most recent echocardiogram, left ventricular ejection fraction was unchanged in 5 patients, improved in 1 patient, and decreased in 1 patient. Notably, both patients with changes from baseline had preexisting allograft dysfunction.

---

### Biphasic versus monophasic cardioversion in shock-resistant atrial fibrillation [^114S2ogX]. Journal of Cardiovascular Electrophysiology (2003). Low credibility.

Unlabelled

Biphasic versus Monophasic Cardioversion.

Introduction

Cardioversion of atrial fibrillation using monophasic transthoracic shocks occasionally is ineffective. Biphasic cardioversion requires less energy than monophasic cardioversion, but its efficacy in shock-resistant atrial fibrillation is unknown. Thus, we compared the efficacy of cardioversion using biphasic versus monophasic waveform shocks in patients with atrial fibrillation previously refractory to monophasic cardioversion.

Methods and Results

Fifty-six patients with prior failed monophasic cardioversion were randomized to either a 360-J monophasic damped sinusoidal shock or biphasic truncated exponential shocks at 150 J, followed by 200 J and then 360 J, if necessary. If either waveform failed, patients were crossed over to the other waveform. The primary endpoint was defined as the proportion of patients achieving sinus rhythm following initial randomized therapy. Stepwise multivariate logistic regression examined independent predictors of shock success, including patient age, sex, left atrial diameter, body mass index, drug therapy, and waveform. Twenty-eight patients were randomized to the biphasic shocks and 28 to the monophasic shocks. Sinus rhythm was restored in 61% of patients with biphasic versus 18% with monophasic shocks (P = 0.001). Seventy-eight percent success was achieved in patients who crossed over to the biphasic shock after failing monophasic cardioversion, whereas only 33% were successfully cardioverted with a monophasic shock after crossover from biphasic shock (P = 0.02). Overall, 69% of patients who received a biphasic shock at any point in the protocol were cardioverted successfully, compared to 21% with the monophasic shock (P < 0.0001). The type of shock was the strongest predictor of shock success (P = 0.0001) in multivariate logistic regression.

Conclusion

An ascending sequence of 150-, 200-, and 360-J transthoracic biphasic cardioversion shocks are successful more often than a single 360-J monophasic shock. Thus, biphasic shocks should be the recommended configuration of choice for all cardioversions.

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^112BvycQ]. Circulation (2024). High credibility.

Regarding medical management for atrial fibrillation, more specifically with respect to rhythm control, electrical cardioversion, ACC/ACCP/AHA/HRS 2024 guidelines recommend to consider using biphasic energy of at least 200 J as initial energy to improve the success of initial electrical shock in patients with AF undergoing elective electrical cardioversion.

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^116xGgvg]. Circulation (2024). High credibility.

Regarding specific circumstances for atrial fibrillation, more specifically with respect to patients with obesity, ACC/ACCP/AHA/HRS 2024 guidelines recommend to consider using manual pressure augmentation and/or further escalation of electrical energy to improve the success of electrical cardioversion in patients with obesity.

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^116H5snQ]. Circulation (2006). Medium credibility.

Quinidine around direct-current cardioversion — A loading dose of quinidine (1200 mg) orally 24 h before direct-current cardioversion significantly reduced the number of shocks and the energy required in persistent atrial fibrillation (AF) and prevented immediate recurrence in 25 cases, whereas recurrence developed in 7 of 25 controls; when quinidine 600 to 800 mg 3 times daily for 2 d failed to convert the rhythm, there was no difference in defibrillation threshold between patients randomized to continue or withdraw the drug.

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^112DsVww]. Circulation (2024). High credibility.

Electrical cardioversion for atrial fibrillation — synchronization, energy strategy, and electrode orientation — is specified as follows: Electrical cardioversion for AF should be synchronized with the QRS complex because unsynchronized or inappropriately synchronized cardioversion can induce VF if delivered during the vulnerable T wave; the synchronization feature must be turned on and visually confirmed before each shock attempt. In a randomized study of 279 patients undergoing synchronized direct current cardioversion with biphasic waveform, first shock success was higher with maximum‑fixed energy (75% compared with 34% for low‑escalating energy group). In the RAFF2 study of recent‑onset, hemodynamically stable AF, an initial biphasic 200 J shock with up to 3 consecutive shocks allowed achieved conversion to sinus rhythm in 176 of 192 (92%) patients. Regarding electrode vectors, when energy output is optimized and AF is of recent onset, either vector orientation may be reasonable, but for longer duration AF the anterior‑posterior orientation may be favorable. Increased body weight has been associated with reduced success of electrical cardioversion; alternatives in refractory cases include the use of 2 defibrillators simultaneously, effectively doubling delivered energy.

---

### Association between defibrillation using LIFEPAK 15 or ZOLL X series and survival outcomes in out-of-hospital cardiac arrest: a nationwide cohort study [^112KwxmV]. Journal of the American Heart Association (2024). Medium credibility.

Discussion

In this nationwide, observational cohort study, we assessed the association between defibrillation using LIFEPAK or ZOLL in the EMS and survival outcomes following OHCA. We found defibrillation using ZOLL was associated with ROSC but not significantly associated with ROSC at hospital arrival or 30‐day survival.

To the best of our knowledge, this is the first comparison of the efficacy of 2 commonly used defibrillators for OHCA. No trials have compared the 2 used biphasic waveforms in adult patients with OHCA. However, several studies compared the efficacy of different defibrillators, including LIFEPAK and ZOLL, in animal cardiac arrest studies and cardioversion for patients without OHCA with diverging results.,

In atrial fibrillation, trials found no significant differences in cardioversion success between LIFEPAK and ZOLL, although the biphasic truncated exponential waveform was more effective than the pulsed biphasic waveform, which uses a similar energy setting as ZOLL. Maximum energy was more efficient compared with low‐escalating energy shocks for cardioversion when using the same waveform. Although data on delivered defibrillation energy were unavailable in this present study, we anticipated that the EMS adhered to the European Resuscitation Council's guidelines using an escalating shock strategy as per manufacturer recommendations.

Two animal studies compared biphasic waveforms for cardiac arrest found the rectilinear waveform superior to the biphasic truncated exponential waveform. Due to fewer shocks required, the rectilinear waveform was more effective in achieving ROSC, thus resulting in shorter total time before successful resuscitation than the biphasic truncated exponential waveform. Furthermore, the rectilinear waveform required significantly less energy than the biphasic truncated exponential waveform for successful defibrillation in a piglet defibrillation model for young children.

The defibrillation characteristics between LIFEPAK and ZOLL differ. LIFEPAK is capable of reaching a higher energy level (360 versus 200 joules) compared with ZOLL. However, the rectilinear waveform delivers greater current for equivalent energy when compared with the biphasic truncated exponential waveform, which is supposed to enhance defibrillation efficacy. Furthermore, the duration of the rectilinear biphasic waveform is fixed at 10 ms regardless of the patient's transthoracic impedance, whereas the duration of the biphasic truncated exponential waveform is adjusted to transthoracic impedance (10–22 ms). Some animal studies suggest waveforms over 10 to 12 ms are associated with a reduced efficacyand an increase in the risk of myocardial dysfunction. However, these studies are based on earlier investigations of monophasic versus biphasic waveforms.

---

### Intravenous administration of magnesium and potassium solution lowers energy levels and increases success rates electrically cardioverting atrial fibrillation [^116DhbHj]. Journal of Cardiovascular Electrophysiology (2012). Low credibility.

Background

External biphasic electrical cardioversion (CV) is a standard treatment option for patients suffering from acute symptoms of atrial fibrillation (AF). Nevertheless, CV is not always successful, and thus strategies to increase the success rate are desirable.

Objective

The purpose of this study was to evaluate the effect of intravenously administered K/Mg solution on the biphasic CV energy threshold and success rate to restore sinus rhythm (SR) in patients with AF.

Methods

The study consisted of 170 patients with persistent AF. The patients were randomly assigned to undergo biphasic CV either with (n = 84) or without (n = 86) pretreatment with K/Mg solution. An energy step-up protocol of 75, 100, and 150 W (J) was used.

Results

Biphasic CV of AF was effective in 81 (96.4%) patients in the pretreatment and 74 (86.0%) patients in the control group (P = 0.005). The effective energy level required to achieve SR was significantly lower in the pretreated group (140.8 ± 26.9 J vs 182.5 ± 52.2 J, P = 0.02). No K/Mg-solution-associated side effects such as hypotension or bradycardia were observed.

Conclusion

Administration of K/Mg solution positively influences the success rate of CV in patients with persistent AF. Furthermore, significantly less energy is required to successfully restore SR and therefore K/Mg pretreatment may facilitate SR restoration in patients undergoing CV for AF.

---

### Cardioversion efficacy using pulsed biphasic or biphasic truncated exponential waveforms: a randomized clinical trial [^115D6jhC]. Journal of the American Heart Association (2017). Low credibility.

Discussion

This is the first randomized clinical study comparing the efficacy of a PB waveform with a BTE waveform demonstrating a higher efficacy for BTE shocks compared with PB shocks in cardioverting AF. There was no difference in safety (ie, myocardial injury measured by changes in troponin I levels).

For every fourth patient cardioverted with BTE shocks, 1 patient would have failed cardioversion if the PB waveform had been used. This substantial amount of failed cardioversions when using PB shocks may have profound clinical implications. The "failed" patients suffered longer time in arrhythmia, may have to be readmitted for another cardioversion attempt, possibly prescribed a concomitant antiarrhythmic drug, or treated with rate control therapy.

The impedance‐compensated (ie, adjusted to differences in chest impedance) PB waveform, which is in clinical use, has not previously been compared to other waveforms. In cardioversion of atrial arrhythmias, a nonimpedance compensated PB waveform was more efficient than a monophasic waveform on the energy used to obtain sinus rhythm in patients with atrial arrhythmias. 8 One study on 104 out‐of‐hospital cardiac arrest patients with shockable rhythm compared a nonimpedance compensated version of the PB waveform to a BTE waveform. 18 The study reported similar defibrillation success rates for PB shocks (90.4%) and the BTE waveform (weighted average 91.8%).

---

### Practice advisory for the perioperative management of patients with cardiac implantable electronic devices: pacemakers and implantable cardioverter-defibrillators 2020: an updated report by the American society of anesthesiologists task force on perioperative management of patients with cardiac implantable electronic devices: erratum [^112otC72]. Anesthesiology (2020). High credibility.

Emergency external cardioversion or defibrillation — advisory recommendations for patients with a cardiac implantable electronic device emphasize minimizing current through the generator and leads and sequencing device-related steps before shocks. During the perioperative period, the cardiac implantable electronic device patient might require emergency external defibrillation or cardioversion, and in this case, a concern is to minimize the current flowing through the pulse generator and leads. Before attempting to emergently externally cardiovert or defibrillate a patient with an implantable cardioverter–defibrillator and magnet-disabled therapies, terminate all sources of electromagnetic interference and remove the magnet to reenable the implantable cardioverter–defibrillator's antitachycardia therapies, then observe the patient for appropriate antitachycardia therapy from the implantable cardioverter–defibrillator and determine the need for reenabling an implantable cardioverter–defibrillator's antitachycardia therapy if it was disabled by programming. If these steps fail to restore antitachycardia therapy, proceed with emergency external cardioversion or defibrillation when needed, follow advanced cardiac life support guidelines for delivered energy level and pad placement, and position pads so they are not directly over the generator to minimize current flow. Use a clinically appropriate energy output regardless of device presence and interrogate the cardiac implantable electronic device immediately after external cardioversion or defibrillation is performed. The consultants and ASA members agree with the recommendation to use anterior–posterior rather than anterior–lateral pad positioning whenever possible.

---

### Impact of defibrillator electrode placement on outcome of electrical cardioversion of atrial fibrillation: a pilot observational study [^1119yHaW]. Journal of the American Heart Association (2024). Medium credibility.

Cardioversion is a commonly performed procedure with a high degree of acute success. The current guidelines recommend cardioversion electrode placement on the basis of standard recommendations, but do not offer anatomic guidance. Prior reports demonstrated success with fluoroscopic‐guided electrode placement after failure of conventional anterior–posterior positioning. In lieu of those observations, we employed fluoroscopic guidance to observe the electrode distance relative to the myocardial target. In the present study, we hypothesized that the alignment of the cardioversion electrode with the cardiac position in the thorax may be suboptimal with standard positioning alone and sought to determine an easy‐to‐identify anatomic landmark.

As previously mentioned, there remains some uncertainty regarding the most optimal cardioversion approach in patients with AF. Kirchhof et al demonstrated the superiority of proper anterior–posterior electrode placement with biphasic shocks. In a multicenter prospective study involving > 5000 patients, anterior–posterior patch placement was associated with a slightly higher success rate compared with anterior–lateral (90% versus 87%). In contrast, a randomized study by Schmidt et al demonstrated the superiority of the anterior–lateral position in achieving sinus rhythm after the first shock when compared with anterior–posterior placement (54% versus 33%). We have adopted the anterior–posterior electrode positioning, in line with the most recent recommendations. In addition, the American Heart Association/American College of Cardiology/Heart Rhythm Societydo not provide specific recommendations on the optimal starting biphasic shock energy for AF, and therefore studies have attempted different approaches with varying success rates. In cases of failure of the first shock, energy escalation and application of external pressure have been recommended to improve efficacy. The concept of MPA in cardioversion arises from the fact the transthoracic impedance is inversely associated with cardioversion success. Applying external force can reduce transthoracic impedance and potentially improve cardioversion success. Ramirez et al demonstrated a 7.4% absolute increase in cardioversion success and an increase in the first shock sustained success with MPA, without serious procedural complications. Therefore, we adopted MPA, a stepwise approach starting with low energy (100 J→200 J→360 J) to avoid postprocedural skin burn and pain and myocardial dysfunction following shock delivery, which have been associated with the use of higher energy levels. The use of MPA on all our patients explains why our 100 J success rate was higher than the 40% to 49% previously reported studies.

---

### State-of-the-art consensus on non-transvenous implantable cardioverter-defibrillator therapy [^111LQsNM]. Clinical Cardiology (2020). Medium credibility.

Abstract

Within the last decade, implantable cardioverter‐defibrillator (ICD) systems with non‐transvenous leads were developed in order to minimize complications related to the cardiovascular position of transvenous ICD leads. This national expert consensus gives an overview of potential indications for the implantation of non‐transvenous ICD systems, and provides specific recommendations for implantation, follow‐up, and complication management in patients with subcutaneous ICD. Regarding particular issues like the necessity for shock efficacy testing, or the clinical outcome as compared to transvenous ICD, randomized data are expected in the near future.

---

### Biphasic versus monophasic shock waveform for conversion of atrial fibrillation: the results of an international randomized, double-blind multicenter trial [^117JuzGY]. Journal of the American College of Cardiology (2002). Low credibility.

Objectives

This study compared a biphasic waveform with a conventional monophasic waveform for cardioversion of atrial fibrillation (AF).

Background

Biphasic shock waveforms have been demonstrated to be superior to monophasic shocks for termination of ventricular fibrillation, but data regarding biphasic shocks for conversion of AF are still emerging.

Methods

In an international, multicenter, randomized, double-blind clinical trial, we compared the effectiveness of damped sine wave monophasic versus impedance-compensated truncated exponential biphasic shocks for the cardioversion of AF. Patients received up to five shocks, as necessary for conversion: 100 J, 150 J, 200 J, a fourth shock at maximum output for the initial waveform (200 J biphasic, 360 J monophasic) and a final cross-over shock at maximum output of the alternate waveform.

Results

Analysis included 107 monophasic and 96 biphasic patients. The success rate was higher for biphasic than for monophasic shocks at each of the three shared energy levels (100 J: 60% vs. 22%, p < 0.0001; 150 J: 77% vs. 44%, p < 0.0001; 200 J: 90% vs. 53%, p < 0.0001). Through four shocks, at a maximum of 200 J, biphasic performance was similar to monophasic performance at 360 J (91% vs. 85%, p = 0.29). Biphasic patients required fewer shocks (1.7 ± 1.0 vs. 2.8 ± 1.2, p < 0.0001) and lower total energy delivered (217 ± 176 J vs. 548 ± 331 J, p < 0.0001). The biphasic shock waveform was also associated with a lower frequency of dermal injury (17% vs. 41%, p < 0.0001).

Conclusions

For the cardioversion of AF, a biphasic shock waveform has greater efficacy, requires fewer shocks and lower delivered energy, and results in less dermal injury than a monophasic shock waveform.

---

### Practice advisory for the perioperative management of patients with cardiac implantable electronic devices: pacemakers and implantable cardioverter-defibrillators 2020: an updated report by the American society of anesthesiologists task force on perioperative management of patients with cardiac implantable electronic devices: erratum [^114Lwk3W]. Anesthesiology (2020). High credibility.

Emergency cardioversion or defibrillation in patients with an implantable cardioverter–defibrillator (within the broader cardiac implantable electronic device [CIED] context) states: "Before attempting to emergently externally cardiovert or defibrillate a patient with an implantable cardioverter–defibrillator and magnet-disabled therapies, terminate all sources of electromagnetic interference and remove the magnet to reenable the implantable cardioverter–defibrillator's antitachycardia therapies", then "Observe the patient for appropriate antitachycardia therapy from the implantable cardioverter–defibrillator" and "Determine the need for re-enabling an implantable cardioverter–defibrillator's antitachycardia therapy if it was disabled by programming". If therapy cannot be restored, "proceed with emergency external cardioversion or defibrillation when needed". Additional steps include to "Follow advanced cardiac life support guidelines for delivered energy level and pad placement", to "Position the cardioversion and defibrillation pads so they are not directly over the cardiac implantable electronic device generator to minimize the current flowing through the generator and leads", to "Use a clinically appropriate energy output regardless of the presence of a cardiac implantable electronic device", and to "Interrogate the cardiac implantable electronic device immediately after external cardioversion or defibrillation is performed".

---

### Cardioversion efficacy using pulsed biphasic or biphasic truncated exponential waveforms: a randomized clinical trial [^117NnJQL]. Journal of the American Heart Association (2017). Low credibility.

End Points

The primary end point and secondary efficacy end points are presented in Table 2. The subgroup analyses of the primary end point are presented in Table 3 (patient's characteristics of the subgroups can be found in Tables S1 and S2).

Table 2
The Primary End Point and the Secondary Efficacy End Points on Successful Cardioversions, ie, the Proportion of Patients in Sinus Rhythm

Table 3
Subgroup Analysis on the Primary End Point, ie, the Proportion of Patients in Sinus Rhythm After 4 Hours

The cumulative success rate at the different energy levels used is shown in Figure 3. As shocks were delivered at 150 and 200 J for both waveforms, we compared cardioversion success at these energies. For 150‐J shocks, the PB waveform success rate was 26% and 40% for the BTE waveform (ratio; 1.5, 95% CI 0.8–2.9, P = 0.2). For shocks at 200 J, the PB shock success rate was 30% and 44% for the BTE waveform (ratio: 1.5, 95% CI 0.7–3.0, P = 0.3). There was no statistical difference in demographic data among patients in whom cardioversion was attempted at 150 and 200 J (data not shown). Moreover, we tested for interaction between the cardioversion efficacy of the 2 waveforms and the 100% oxygen/room air intervention. The interaction between the interventions was not significant (P = 0.3) and, furthermore, there was no difference between 100% oxygen and room air on cardioversion efficacy either with (P = 0.46) or without (P = 0.84) adjustment for the waveform used.

Figure 3
The figure shows the energy in joules (J) delivered (90–250 J) against the cumulative cardioversion success of the 2 waveforms used.indicates biphasic truncated exponential;, pulsed biphasic.

---

### BIPHASIC trial: a randomized comparison of fixed lower versus escalating higher energy levels for defibrillation in out-of-hospital cardiac arrest [^112wWjJ8]. Circulation (2007). Low credibility.

Background

There is little clear evidence as to the optimal energy levels for initial and subsequent shocks in biphasic waveform defibrillation. The present study compared fixed lower- and escalating higher-energy regimens for out-of-hospital cardiac arrest.

Methods and Results

The Randomized Controlled Trial to Compare Fixed Versus Escalating Energy Regimens for Biphasic Waveform Defibrillation (BIPHASIC Trial) was a multicenter, randomized controlled trial of 221 out-of-hospital cardiac arrest patients who received ≥ 1 shock given by biphasic automated external defibrillator devices that were randomly programmed to provide, blindly, fixed lower-energy (150–150–150 J) or escalating higher-energy (200–300–360 J) regimens. Patient mean age was 66.0 years; 79.6% were male. The cardiac arrest was witnessed in 63.8%; a bystander performed cardiopulmonary resuscitation in 23.5%; and initial rhythm was ventricular fibrillation/ventricular tachycardia in 92.3%. The fixed lower- and escalating higher-energy regimen cases were similar for the 106 multishock patients and for all 221 patients. In the primary analysis in multishock patients, conversion rates differed significantly (fixed lower, 24.7%, versus escalating higher, 36.6%; P = 0.035; absolute difference, 11.9%; 95% CI, 1.2 to 24.4). Ventricular fibrillation termination rates also were significantly different between groups (71.2% versus 82.5%; P = 0.027; absolute difference, 11.3%; 95% CI, 1.6 to 20.9). For the secondary analysis of first shock success, conversion rates were similar between the fixed lower and escalating higher study groups (38.4% versus 36.7%; P = 0.92), as were ventricular fibrillation termination rates (86.8% versus 88.8%; P = 0.81). There were no distinguishable differences between regimens for survival outcomes or adverse effects.

Conclusions

This is the first randomized trial to compare fixed lower and escalating higher biphasic energy regimens in out-of-hospital cardiac arrest, and it demonstrated higher rates of ventricular fibrillation conversion and termination with an escalating higher-energy regimen for patients requiring multiple shocks. These results suggest that patients in ventricular fibrillation benefit from higher biphasic energy levels if multiple defibrillation shocks are required.

---

### Biphasic and monophasic shocks for transthoracic defibrillation: a meta analysis of randomised controlled trials [^116UAU8n]. Resuscitation (2003). Low credibility.

Introduction

Biphasic waveforms are routinely used for implantable defibrillators. These waveforms have been less readily adopted for external defibrillation. This study was performed in order to evaluate the efficacy and harms of biphasic waveforms over monophasic waveforms for the transthoracic defibrillation of patients in ventricular fibrillation (VF) or haemodynamically unstable ventricular tachycardia.

Methods

Studies included randomised controlled trials comparing monophasic and biphasic external defibrillation for participants with VF or hemodynamically unstable ventricular tachycardia. Seven trials (1129 patients) were included in the analysis. All trials were conducted during electrophysiology procedures or implantable cardioverter/defibrillator testing.

Results

Compared with 200 J monophasic shocks, 200 J biphasic shocks reduced the risk of post-first shock asystole or persistent VF by 81% (relative risk (RR) 0.19; 95% confidence intervals (CI) 0.06–0.60) for the first shock. Reducing the energy of the biphasic waveform to 115–130 J resulted in similar effectiveness compared with the monophasic waveform at 200 J (RR 1.07, CI 0.66–1.74). Low energy biphasic shocks produce less myocardial injury than higher energy monophasic shocks as determined by ST segment deflection after shock.

Conclusions

Biphasic waveforms defibrillate with similar efficacy at lower energies than standard 200 J monophasic waveforms, and greater efficacy than monophasic shocks of the same energy. Available data suggests that lower delivered energy and voltage result in less post-shock myocardial injury.

---

### The function of cochlear implant after cardioversion in a patient with atrial flutter: a case report [^1158epDN]. Ear, Nose, & Throat Journal (2023). Medium credibility.

Hearing loss in older people can cause communication impairments, decreased quality of life, social isolation, depression, and dementia. Cochlear implant surgery is an effective treatment for older patients with hearing loss who cannot achieve satisfactory audiologic outcomes with hearing aids. However, older people have an increased risk of heart disease and often take medications that affect heart rhythm. Herein, we report a case of an 80-year-old woman who underwent cardioversion at 50J after cochlear implant surgery. Electrical impedance before and after cardioversion showed only minor changes without abnormality, and the cochlear implant functioned well. We believe that the electronic circuits of the cochlear implant may have been relatively tolerant to the electrical shock from the external defibrillator. Typically, cardioversion should be avoided in cochlear implant recipients because it may damage the implant. If cardioversion cannot be avoided, we strongly recommend starting cardioversion at the lowest energy level (50 J) and removing the sound processor of the implant during the procedure.

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^114mWJUi]. Circulation (2006). Medium credibility.

Atrial fibrillation — management of implanted cardiac devices during cardioversion emphasizes interrogation/reprogramming and external pad positioning to minimize device effects. To ensure appropriate function, the implanted device should be interrogated and, if necessary, reprogrammed before and after cardioversion, and the paddles used for external cardioversion should be positioned as distantly as possible, preferably in the anterior-posterior configuration. The risk of exit block is greater when one paddle is positioned near the impulse generator and the other over the cardiac apex, and lower with the anterior-posterior electrode configuration and with bipolar electrode systems; low-energy internal cardioversion does not interfere with pacemaker function in patients with electrodes positioned in the RA, coronary sinus, or left pulmonary artery.

---

### Investigating the efficacy of chest pressure for direct current cardioversion in atrial fibrillation: a randomised control trial protocol (pressure-AF) [^112VTaTm]. Open Heart (2021). Medium credibility.

Introduction

Atrial fibrillation (AF) is the most common sustained arrhythmia worldwide. Direct current cardioversion is commonly used to restore sinus rhythm in patients with AF. Chest pressure may improve cardioversion success through decreasing transthoracic impedance and increasing cardiac energy delivery. We aim to assess the efficacy and safety of routine chest pressure with direct current cardioversion for AF.

Methods and analysis

Multicentre, double blind (patient and outcome assessment), randomised clinical trial based in New South Wales, Australia. Patients will be randomised 1:1 to control and interventional arms. The control group will receive four sequential biphasic shocks of 150 J, 200 J, 360 J and 360 J with chest pressure on the last shock, until cardioversion success. The intervention group will receive the same shocks with chest pressure from the first defibrillation. Pads will be placed in an anteroposterior position. Success of cardioversion will be defined as sinus rhythm at 1 min after shock. The primary outcome will be total energy provided. Secondary outcomes will be success of first shock to achieve cardioversion, transthoracic impedance and sinus rhythm at post cardioversion ECG.

Ethics and dissemination

Ethics approval has been confirmed at all participating sites via the Research Ethics Governance Information System. The trial has been registered on the Australia New Zealand Clinical Trials Registry (ACTRN12620001028998). De-identified patient level data will be available to reputable researchers who provide sound analysis proposals.

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^11342LYc]. Circulation (2006). Medium credibility.

Atrial fibrillation (AF) direct-current cardioversion — procedural aspects and energy selection: Cardioversion should be performed with the patient under adequate general anesthesia in a fasting state, and the electric shock should be synchronized with the QRS complex triggered by monitoring the R wave on an electrocardiogram (ECG). The initial energy may be low for atrial flutter but higher energy is required for AF; energy has traditionally been increased in increments of 100 J to a maximum of 400 J, and to avoid myocardial damage some have suggested that the interval between consecutive shocks should be at least 1 min. In 64 patients assigned to initial monophasic energies of 100, 200, or 360 J, immediate success rates were 14%, 39%, and 95%, respectively, leading to the conclusion that an initial energy of 200 J or greater is recommended, with a similar recommendation to start with 200 J for biphasic waveforms. For AF, rectilinear biphasic waveform cardioversion was more effective than monophasic sinusoidal (99.1% vs 92.4%), and the median successful energy level was 100 J with the biphasic waveform compared with 200 J with the monophasic waveform.

---

### Improved survival to hospital discharge in pediatric in-hospital cardiac arrest using 2 Joules / kilogram as first defibrillation dose for initial pulseless ventricular arrhythmia [^115gdwBX]. Resuscitation (2020). Medium credibility.

The American Heart Association (AHA) recommends first defibrillation energy dose of 2 Joules/kilogram (J/kg) for pediatric cardiac arrest with ventricular fibrillation (VF) or pulseless ventricular tachycardia (pVT). However, optimal first energy dose remains unclear.

Methods

Using AHA Get With the Guidelines-Resuscitation® (GWTG-R) database, we identified children ≤ 12 years with IHCA due to VF/pVT. Primary exposure was energy dose in J/kg. We categorized energy doses: 1.7–2.5 J/kg as reference (reflecting 2 J/kg intended dose), < 1.7 J/kg and > 2.5 J/kg. We compared survival for reference doses to all other doses. We constructed models to test association of energy dose with survival; adjusting for age, location, illness category, initial rhythm and vasoactive medications.

Results

We identified 301 patients ≤ 12 years with index IHCA and initial VF/pVT. Survival to discharge was significantly lower with energy doses other than 1.7–2.5 J/kg. Individual dose categories of < 1.7 J/kg or > 2.5 J/kg were not associated with differences in survival. For patients with initial VF, doses > 2.5 J/kg had worse survival compared to reference. For all patients ≤ 18 years (n = 422), there were no differences in survival between dosing categories. However, all ≤ 18 with initial VF receiving > 2.5 J/kg had worse survival.

Conclusions

First energy doses other than 1.7–2.5 J/kg are associated with lower rate of survival to hospital discharge in patients ≤ 12 years old with initial VF/pVT, and first doses > 2.5 J/kg had lower survival rates in all patients ≤ 18 years old with initial VF. These results support current AHA guidelines for first pediatric defibrillation energy dose of 2 J/kg.

---

### Comparison of monophasic and biphasic shocks for transthoracic cardioversion of atrial fibrillation [^115fWCxY]. Heart (2003). Low credibility.

Objective

To compare the efficacy of cardioversion in patients with atrial fibrillation between monophasic damped sine waveform and rectilinear biphasic waveform shocks at a high initial energy level and with a conventional paddle position.

Design

Prospective randomised study.

Patients and Setting

227 patients admitted for cardioversion of atrial fibrillation to a tertiary referral centre.

Results

70% of 109 patients treated with an initial 200 J monophasic shock were cardioverted to sinus rhythm, compared with 80% of 118 patients treated with an initial 120 J biphasic shock (NS). After the second shock (360 J monophasic or 200 J biphasic), 90% of the patients were in sinus rhythm in both groups. The mean cumulative energy used for successful cardioversion was 306 J for monophasic shocks and 159 J for biphasic shocks (p < 0.001).

Conclusions

A protocol using monophasic waveform shocks in a 200–360 J sequence has the same efficacy (90%) as a protocol using rectilinear biphasic waveform shocks in a 120–200 J sequence. This equal efficacy is achieved with a significantly lower mean delivered energy level using the rectilinear biphasic shock waveform. The potential advantage of lower energy delivery for cardioversion of atrial fibrillation needs further study.

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^111pV5Xi]. Circulation (2024). High credibility.

Regarding medical management for atrial fibrillation, more specifically with respect to rhythm control, electrical cardioversion, ACC/ACCP/AHA/HRS 2024 guidelines recommend to consider optimizing electrode vector, using higher energy, and administering pretreatment with antiarrhythmic drugs to facilitate the success of electrical cardioversion in patients with AF undergoing elective cardioversion with longer duration of AF or unsuccessful initial shock.

---

### Abatacept, cenicriviroc, or infliximab for treatment of adults hospitalized with COVID-19 pneumonia… [^113kMjex]. JAMA Network (2023). Excellent credibility.

O'Halloran JA, Ko ER, Anstrom KJ, et al. Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA. 2023; 330: 328–339. doi: 10.1001/jama.2023.11043 Trial protocol eTables and eFigures Nonauthor collaborators Data sharing statement aOne participant with estimated glomerular filtration rate < 30 mL/min, known or suspected history of untreated tuberculosis, male or pregnant female < 18 years at enrollment, neutropenia, no ongoing illness and radiographic infiltrates by imaging, oxygen saturation as measured by pulse oximetry ≤ 94% on room air, requiring supplemental oxygen, or requiring mechanical ventilation/extracorporeal membrane oxygenation. Medications disrupting IL-6 signaling and the Janus kinase pathway show benefit in the most severely ill patients with COVID-19.

5–9 In April 2020, the US National Institutes of Health launched a public-private partnership, Accelerating COVID-19 Therapeutic Interventions and Vaccines, to develop a coordinated research response to COVID-19. The term cytokine storm describes the marked increase in cytokines that triggers a cascade of synergistic inflammatory signaling in severe disease. 2 Aberrant T-cell function in severe COVID-19 is complex, involving hyperactivation of CD4+ T cells. 1 Circulating monocytes and macrophages also play a key role in inflammatory signaling and fibrosis. 21 Subtleties in ACTIV-1 substudies hint at small differences in therapeutic roles. A key clinical question involves how to treat hospitalized patients receiving low-flow oxygen. Current NIH guidelines do not recommend addition of a second immunomodulator for these patients in the absence of rapidly increasing oxygen needs.

The ACTIV-1 IM substudies begin to address this critical question, showing reduced mortality for participants receiving abatacept or infliximab in a general population of participants of all ordinal scales independent of inflammatory markers. Subgroup analysis suggests that the benefits in mortality occur for participants receiving both low-flow and high-flow oxygen/noninvasive ventilation.

---

### Electrical energy by electrode placement for cardioversion of atrial fibrillation: a systematic review and meta-analysis [^114wWRZ2]. Open Heart (2023). Medium credibility.

Assessment of risk of bias of the included trials showed some concerns in two trials. Four out of five trials did not report any method for allocation concealment, which may increase the risk of selection bias. Due to the nature of the studies, blinding of personnel and trialists was impossible, though the open-label design was not thought to influence the outcome assessment. Only one trial had blinded outcome adjudication, and only two trials were rated as having low risk of bias.

Participants in the included studies differed with respect to age, weight, comorbidities, duration of AF and use of antiarrhythmics drugs. For example, the user rate of amiodarone varied from 9% to 10% in one trialto from 40% to 50% in another trial. Such factors are known to influence the cardioversion rate. Selected studies used slightly different methods to ascertain success as well as different step-up protocols with initial low-energy shock, the latter not being in line with contemporary practice. Furthermore, electrode placement, specifically the anteroposterior electrode placement, was slightly different (eg, right infraclavicular or left infraclavicular) between the trials. Differences in anteroposterior position could, theoretically, target the atrium differently and therefore be of significance in cardioversion success. Only 4% of the transthoracic shock traverses the heart while the rest of the current is shunted around the heart and through the thoracic cage and lungs. Therefore, a successful cardioversion could be more dependent on the total energy delivery rather than electrode placement, a trend that was observed in all RCTs.

Schmidt et al showed that adverse events, for example, arrhythmias and transient bradycardia, were rare. Other adverse effects such as skin discomfort was rarely experienced. A recent study by Lobo et al examined the effect of high-energy biphasic shock cardioversion on high-sensitive troponin release, and even when delivering 360J shocks, an increase in troponin release could not be detected; hence, cardioversion should be considered a safe procedure, even at high energy shock delivery. One randomised trial demonstrated that maximum fixed energy shocks of 360J had higher conversion rates compared with sequential and escalating shock energies. However, considering the high conversion rates at 200J, independent of electrode position, it can be speculated that electrode position becomes irrelevant when delivering high energy shocks (≥ 200J).

---

### Part 9: adult advanced life support: 2025 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care [^115wzq45]. Circulation (2025). High credibility.

Regarding medical management for cardiac arrest, more specifically with respect to management of wide-complex tachycardia, cardioversion, AHA 2025 guidelines recommend to perform synchronized cardioversion for acute treatment of patients with hemodynamically unstable wide-complex tachycardia.

---

### Part 9: adult advanced life support: 2025 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care [^115D3mAX]. Circulation (2025). High credibility.

Regarding medical management for cardiac arrest, more specifically with respect to management of narrow-complex tachycardia, cardioversion, AHA 2025 guidelines recommend to perform synchronized cardioversion for acute treatment of patients with hemodynamically unstable narrow-complex tachycardias.

---

### Biphasic energy selection for transthoracic cardioversion of atrial fibrillation. the BEST AF trial [^114J8rWo]. Heart (2008). Low credibility.

Aims

To compare the efficacy and safety of an escalating energy protocol with a non-escalating energy protocol using an impedance compensated biphasic defibrillator for direct current cardioversion of atrial fibrillation (AF).

Methods and Results

This prospective multicentre randomised trial enrolled 380 patients (248 male, mean (SD) age 67 (10) years) with AF. Patients were randomised to either an escalating energy protocol (protocol A: 100 J, 150 J, 200 J, 200 J), or a non-escalating energy protocol (protocol B: 200 J, 200 J, 200 J). Cardioversion was performed using an impedance compensated biphasic waveform. First-shock success was significantly higher for those randomised to 200 J than 100 J (71% vs 48%; p < 0.01) and for patients with a body mass index (BMI) > 25 kg/m² (75% vs 44%; p = 0.01). In patients with a normal BMI there was no significant difference in first-shock success. There was also no significant difference between subsequent shocks or overall success. The use of a non-escalating protocol (protocol B) resulted in fewer shocks but with a higher cumulative energy. There was no difference in duration of procedure, amount of sedation administered or post-shock erythema between the groups.

Conclusion

First-shock success was significantly higher, particularly in patients with a BMI > 25 kg/m², when a non-escalating initial 200 J energy was selected. The overall success, duration of procedure and amount of sedation administered, however, did not differ significantly between the two protocols.

---

### Optimization of initial energy for cardioversion of atrial tachyarrhythmias with biphasic shocks [^1162oWow]. The American Journal of Emergency Medicine (2010). Low credibility.

Objective

Recommendations for optimal first-shock energies with biphasic waveforms are conflicting. We evaluated prospectively the relation between type and duration of atrial tachyarrhythmias and the probability of successful cardioversion with a specific biphasic shock waveform to develop recommendations for the initial energy setting aiming at the lowest total cumulative energy with 2 or less consecutive shocks.

Methods

We analyzed 453 consecutive patients undergoing their first transthoracic electrical cardioversion, including 358 attempts for atrial fibrillation (AF) and 95 attempts for atrial flutter (AFL) or atrial tachycardia (AT). A step-up protocol with a truncated exponential biphasic waveform starting at 50 J was used. Total cumulative energies were estimated under the assumption of a 2-tiered escalating shock protocol with different initial energy settings and a "rescue shock" of 250 J for AFL/AT or 360 J for AF. The initial energy setting leading to the lowest total cumulative energy was regarded as the optimal first-shock level.

Results

Cardioversion was successful in 448 patients (cumulative efficacy, 99%). In patients with AFL/AT, the lowest total cumulative energy was attained with an initial energy setting of 50 J. In patients with AF, lowest values were achieved with an initial energy of 100 J for arrhythmia durations of 2 days or less and an initial energy of 150 J for arrhythmia durations of more than 2 days.

Conclusion

We recommend an initial energy setting of 50 J in patients with AFL/AT, of 100 J in patients with AF 2 days or less, and of 150 J with AF more than 2 days.

---

### Evidence-based guidelines for the use of defibrillation pads [^113v59qB]. Resuscitation (2001). Low credibility.

Objective

Defibrillation pads are used routinely at both cardiac arrests and cardioversion procedures. There are currently no evidence-based guidelines on how often pads should be replaced, although it has been suggested that they should be changed as often as every three shocks to maintain optimal performance. Previously, we have shown that on exposure to air, pad mass diminishes over time due to evaporation — an effect likely to lead to poorer conduction between skin and paddle. This prospective study was designed to determine if evaporation is accelerated by the passage of a defibrillation current and to formulate evidence-based guidelines for defibrillation pad replacement.

Materials and Methods

3M defibrillation pads (2346N) were collected from acute wards and emergency departments in two hospitals in the UK over a 2 month period. The duration of exposure to air, number and energy of shocks, and type of procedure were recorded. When no longer required, pad masses were determined and the loss of pad mass due to evaporation calculated.

Results

26 pairs of pads were collected from 14 cardiac arrests and 12 cardioversions. The total defibrillation energy used ranged from 150 to 5080 J and evaporative drying time from 4 to 38 min. The rate of evaporation from these pads (86.1 mg × min⁻¹) was not significantly different from pads previously studied on volunteers in the absence of a defibrillation current (99.4 mg × min⁻¹). Of the defibrillation pads exposed to air for less than 30 min, in only one of 49 pads was the loss of mass due to evaporation consistent with a significant increase in transthoracic impedance (TTI). Correspondingly, of two pads used for more than 30 min, both attained a mass consistent with a significant increase in TTI.

Conclusions

Defibrillation pads can be used for up to 30 min without evaporation causing a clinically significant increase in TTI. The passage of a defibrillation current across pads does not further accelerate water loss.

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^112DEh1K]. Circulation (2024). High credibility.

Regarding medical management for atrial fibrillation, more specifically with respect to rhythm control, electrical cardioversion, ACC/ACCP/AHA/HRS 2024 guidelines recommend to confirm energy delivery is synchronized to the QRS to reduce the risk of inducing VF in patients with AF undergoing electrical cardioversion.

---

### A national model for developing, implementing, and evaluating evidence-based guidelines for prehospital care [^116thZuB]. Academic Emergency Medicine (2012). Medium credibility.

Cardiovascular — Tachycardia with a Pulse (cardioversion energy and supraventricular tachycardia therapy): Biphasic waveforms have been proven to convert A-FIB at lower energies and higher rates of success than monophasic waveforms. Strategies include dose escalation (70, 120, 150, 170 joules (J) for biphasic or 100, 200, 300, 360 J for monophasic) versus beginning with single high energy/highest success rate for single shock delivered. Studies in infants and children have demonstrated the effectiveness of adenosine for the treatment of hemodynamically stable or unstable supraventricular tachycardia (SVT). Adenosine should be considered the preferred medication for stable SVT; verapamil may be considered as alternative therapy in older children but should not be routinely used in infants. Procainamide or amiodarone given by a slow IV infusion with careful hemodynamic monitoring may be considered for refractory SVT.

---

### Electrical energy by electrode placement for cardioversion of atrial fibrillation: a systematic review and meta-analysis [^111pxHTP]. Open Heart (2023). Medium credibility.

Data collection process

Two reviewers extracted all data independently and in duplicate. We evaluated study characteristics, including trial location, whether patients with recent-onset or persistent AF were included, inclusion and exclusion criteria, and the shock protocol (energy level of shocks and step-up protocol). We also assessed patient characteristics, including mean age, mean body mass index, proportion of men and proportion of patients with hypertension.

We examined restoration of sinus rhythm by delivered energy (dose–response evaluation). The outcomes of interest were restoration of sinus rhythm after the first shock in a step-up protocol using increasing electrical current, and restoration of sinus rhythm after the final shock. The final shock was either the shock that led to restoration of sinus rhythm or the final shock in the study-specific shock protocol. From each study, we collected the total number of patients and the number of patients with restored sinus rhythm after the first shock and after all consecutive shocks. We extracted the outcome data for success as defined according to each study-specific protocol (table 1). Some RCTs used a step-up protocol, which included sequential shocks with increasing energy and a final cross-over of electrodes (switching from the initial allocated position to the alternate position on cardioversion failure). In studies with cross-over protocols, we considered the final shock as the last one in the allocated electrode position and not after cross-over. Trial investigators were contacted to obtain missing data. In Muñoz-Martínez et al 's study, we used the first of two shocks with 200J for the dose–response analysis.

Table 1
Study characteristics

Assessment of risk of bias

Reviewers assessed within-study biases with the RoB 2 Tool (version 2 of the Cochrane risk-of-bias tool for randomised trials). This tool provided a framework for the assessment of the overall risk of bias by evaluating: (1) the randomisation process, (2) deviations from the intended procedure, (3) missing outcome data, (4) measurement of outcome and (5) selective reporting. To assess small-study effects, we created funnel plots for the first and final shock conversion success outcomes.

---

### Electrical energy by electrode placement for cardioversion of atrial fibrillation: a systematic review and meta-analysis [^112y1rRZ]. Open Heart (2023). Medium credibility.

Synthesis methods

We calculated the cumulative proportions of patients with restored sinus rhythm by cumulative shocks and estimated risk ratios (RRs). For example, when counting patients with restored sinus rhythm after the second shock, patients with restored sinus rhythm after both the first and second shock were included in the numerator and all patients were included in the denominator. The RRs were pooled across eligible studies by using inverse-variance random-effects models. We used the Paule-Mandel procedure to estimate the between-trial variance with the Knapp-Hartung adjustment procedure. To quantify heterogeneity between studies, we also estimated the I² statistic. To examine the effect of shock energy, we conducted a dose–response meta-analysis to assess the association of shock energy with the probability of restored sinus rhythm, for each electrode position separately. In each study, we extracted the cumulative number of patients with restored sinus rhythm at each increasing energy level; we assumed that patients with success at lower energy levels would have success at a given energy level. We fitted a one-stage random-effects dose–response model using restricted cubic splines with three knots for each electrode position. As all studies delivered a 200J shock, this amount of energy was used as the reference level in this analysis.

All analyses were performed in R V.4.0.3. with the 'meta' package, except the dose–response model that we fitted with Stata V.15.1 by using the command drmeta.

---

### Investigating the efficacy of chest pressure for direct current cardioversion in atrial fibrillation: a randomised control trial protocol (pressure-AF) [^1113DCb7]. Open Heart (2021). Medium credibility.

Sample size and power calculation

Power calculation was performed based on a retrospective analysis of direct current cardioversions over the prior year. The mean energy provided per encounter for cardioversion in AF was 280 ± 188 J. Assuming a mean reduction of 60 J in energy in the intervention group (approximately one-third of the SD), a total of 308 patients would be required for an alpha of 0.05 and power of 80%. An interim analysis will be performed at 12 months to ensure adequate recruitment (at least 30% of the target) and no safety signals. Trial recruitment has begun, and 11 patients have been enrolled.

Statistical analysis

Continuous variables will be reported as mean ± SD or as median and percentiles. Normally distributed variables will be compared using the paired Student's t-test. Otherwise, comparisons between both the groups will be performed using the Mann-Whitney U test. Categorical variables will be stated as absolute and relative frequencies and compared using the χ² test. All tests are two-tailed. A p value of < 0.05 will be considered statistically significant. Pre-specified post hoc analyses will be performed based on body mass index, left atrial size, age, antiarrhythmic therapy and duration of AF (online supplemental file 1).

---

### 2019 ESC guidelines for the management of patients with supraventricular tachycardiaThe task force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC) [^113g4uQF]. European Heart Journal (2020). High credibility.

Regarding therapeutic procedures for supraventricular tachyarrhythmias, more specifically with respect to synchronized electrical cardioversion, ESC 2020 guidelines recommend to perform synchronized direct current cardioversion for acute management of hemodynamically stable patients with either narrow or wide QRS tachycardia, if medical therapy fails to convert or control the tachycardia, in the absence of an established diagnosis.

---

### Part 9: adult advanced life support: 2025 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care [^112LHwQr]. Circulation (2025). High credibility.

Regarding medical management for cardiac arrest, more specifically with respect to management of AF/atrial flutter, cardioversion, AHA 2025 guidelines recommend to recognize that the usefulness of double synchronized cardioversion of AF in adults as an initial treatment strategy is uncertain.

---

### Automated external defibrillation in the occupational setting [^114MLQbg]. Journal of Occupational and Environmental Medicine (2012). Medium credibility.

Defibrillation energy and post-shock actions — biphasic truncated exponential waveform in pulseless VT/VF — are specified as follows: It is reasonable to start with an energy level of 150 to 200 J; shock success is usually defined as termination of VF 5 seconds after the shock; when defibrillation is required, a single shock should be followed with resumption of chest compressions/CPR immediately after the shock; chest compressions should not be delayed for rhythm analysis or a pulse check immediately after a shock; and for second and subsequent biphasic shocks, the same initial energy level is acceptable.

---

### A national model for developing, implementing, and evaluating evidence-based guidelines for prehospital care [^111D4xts]. Academic Emergency Medicine (2012). Medium credibility.

Cardiovascular tachycardia with a pulse quality improvement lists associated NEMSIS protocol codes 9914147 — Medical - Supraventricular Tachycardia (including A-FIB), 9914151 — Medical - Ventricular Tachycardia (with pulse), and 9914199 — Medical-Tachycardia; specifies key documentation elements (initial rhythm and all rhythm changes; time, dose, and response to medications given; cardioversion times, synchronization, attempts, joules, and response; obtain monitor strips after each intervention; patient weight; pediatric length-based tape color [for pediatrics who fit on tape]; and history of event supporting treatment of underlying causes); and identifies performance measures (time to clinical improvement from patient contact; blood sugar obtained; correct medication(s) and dose given for patient condition, age, and weight; correct cardioversion joules delivered given patient weight and/or condition; and use of sedation for responsive patient), along with National EMS Quality Alliance (NEMSQA) measures Hypoglycemia — 01: Treatment Administered for Hypoglycemia and Pediatrics — 03: Documentation of Estimated Weight in Kilograms.

---

### Cardioversion efficacy using pulsed biphasic or biphasic truncated exponential waveforms: a randomized clinical trial [^1166Bys4]. Journal of the American Heart Association (2017). Low credibility.

Background

Several different defibrillators are currently used for cardioversion and defibrillation of cardiac arrhythmias. The efficacy of a novel pulsed biphasic waveform has not been compared to other biphasic waveforms. Accordingly, this study aims to compare the efficacy and safety ofshocks with biphasic truncated exponential shocks in patients undergoing cardioversion of atrial fibrillation or ‐flutter.

Methods and Results

This prospective, randomized study included patients admitted for elective direct current cardioversion. Patients were randomized to receive cardioversion using eitherorshocks. We used escalating shocks until sinus rhythm was obtained or to a maximum of 4 shocks. Patients randomized toshocks received 90, 120, 150, and 200 J and patients randomized toshocks received 100, 150, 200, and 250 J, as recommended by the manufacturers. In total, 69 patients (51%) receivedshocks and 65 patients (49%)shocks. Successful cardioversion, defined as sinus rhythm 4 hours after cardioversion, was achieved in 43 patients (62%) usingshocks and in 56 patients (86%) usingshocks; ratio 1.4 (95% CI 1.1–1.7) (P = 0.002). There was no difference in safety (ie, myocardial injury judged by changes in high‐sensitive troponin I levels; ratio 1.1) (95% CI 1.0–1.3), P = 0.15. The study was terminated prematurely because of an adverse event.

Conclusions

Cardioversion using awaveform was more effective when compared with awaveform. There was no difference in safety between the 2 waveforms, as judged by changes in troponin I levels.

Clinical Trial Registration

Unique identifier:02317029.